

Unit 2:

Bacterial Genetics and the Chemical Control of Bacteria

I. Bacterial Genetics: Horizontal Gene Transfer; Quorum Sensing, Pathogenicity Islands, and Secretion Systems; Enzyme Regulation.

II. Using Antibiotics and Chemical Agents to Control Bacteria: Modes of Action for Control Agents; Bacterial Resistance to Control Agents.

III. The Eukaryotic Cell: Eukaryotic Cell Anatomy.

bacterium. This results in a transfer of some chromosomal DNA from the donor to the recipient which may be exchanged for a piece of the recipient's DNA through homologous recombination.

Common Course Objectives

1. Compare and contrast mutation and horizontal gene transfer as methods of enabling bacteria to respond to selective pressures and adapt to new environments.
2. Briefly describe the mechanisms for transformation in bacteria.
3. Differentiate between generalized transduction and specialized transduction.
4. Briefly describe the mechanisms for the transfer of conjugative plasmids, conjugative transposons, and mobilizable plasmids in Gram-negative bacteria.
5. Differentiate between F⁺ conjugation and Hfr conjugation.
6. Describe mechanisms of how a normally commensalistic bacterium can become pathogenic.

Detailed Learning Objectives

- 1*. Compare and contrast mutation and horizontal gene transfer as methods of enabling bacteria to respond to selective pressures and adapt to new environments.
- 2*. Define horizontal gene transfer and state the most common form of horizontal gene transfer in bacteria.
3. Briefly describe the mechanisms for transformation in bacteria.
4. Briefly describe the following mechanisms of horizontal gene transfer in bacteria:
 - a. generalized transduction
 - b. specialized transduction
5. Briefly describe the following mechanisms of horizontal gene transfer in bacteria:
 - a**. Transfer of conjugative plasmids, conjugative transposons, and mobilizable plasmids in Gram-negative bacteria
 - b. F⁺ conjugation
 - c. Hfr conjugation
- 6*. Describe R-plasmids and the significance of R-plasmids to medical microbiology.

(*) = Common theme throughout the course

(**) = More depth and common theme

TPS Questions

Mutation and Horizontal Gene Transfer in Bacteria

Bacteria are able to **respond to selective pressures and adapt to new environments** by acquiring new genetic traits as a result of **mutation, a modification of gene function within a bacterium**, and as a result of **horizontal gene transfer, the acquisition of new genes from other bacteria**.

Mutation occurs relatively slowly. The normal mutation rate in nature is in the range of 10^{-6} to 10^{-9} per nucleotide per bacterial generation, although when bacterial populations are under stress, they can greatly increase their mutation rate. Furthermore, **most mutations are harmful to the bacterium**.

For more information: Review of mutation.

Horizontal gene transfer, on the other hand, **enables bacteria to respond and adapt to their environment much more rapidly by acquiring large DNA sequences from another bacterium** in a single transfer.

In this section we will look at horizontal gene transfer.

Horizontal gene transfer, also known as lateral gene transfer, **is a process in which an organism transfers genetic material to another organism that is not its offspring**. The ability of Bacteria and Archaea to adapt to new environments as a part of bacterial evolution most frequently results from the acquisition of new genes through horizontal gene transfer rather than by the alteration of gene functions through mutations. (It is estimated that as much as 20% of the genome

of *Escherichia coli* originated from horizontal gene transfer.)

Horizontal gene transfer is able to cause rather large-scale changes in a bacterial genome. For example, certain bacteria contain **multiple virulence genes called pathogenicity islands** that are located on large, unstable regions of the bacterial genome. These pathogenicity islands can be transmitted to other bacteria by horizontal gene transfer. However, if these transferred genes provide no selective advantage to the bacteria that acquire them, they are usually lost by deletion. In this way the size of the bacterium's genome can remain approximately the same size over time.

There are three mechanisms of horizontal gene transfer in bacteria: **transformation, transduction, and conjugation**. **The most common mechanism for horizontal gene transmission among bacteria, especially from a donor bacterial species to different recipient species, is conjugation**. Although bacteria can acquire new genes through transformation and transduction, this is usually a more rare transfer among bacteria of the same species or closely related species.

Self Check




Transformation

Transformation is a form of genetic recombination in which **a DNA fragment from a dead, degraded bacterium enters a competent recipient bacterium and is exchanged for a piece of DNA of the recipient**. Transformation usually involves only **homologous recombination**, a recombination of homologous DNA sequences having nearly the same nucleotide sequences. Typically this involves similar bacterial strains or strains of the same bacterial species.

A few bacteria, such as *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Hemophilus influenzae*, *Legionella pneumophila*, *Streptococcus pneumoniae*, and *Helicobacter pylori* tend to be **naturally competent and transformable**. Competent bacteria are able to bind much more DNA than noncompetent bacteria. Some of these genera also undergo autolysis that then provides DNA for homologous recombination. In addition, some competent bacteria kill noncompetent ones in order to release DNA for transformation.

During transformation, **DNA fragments** (usually about 10 genes long) **are released from a dead degraded bacterium and bind to DNA binding proteins on the surface of a competent living recipient bacterium**. Depending on the bacterium, **either both strands of DNA penetrate the recipient, or a nuclease degrades one strand of the fragment and the remaining DNA strand enters the recipient**. **This DNA fragment from the donor is then exchanged for a piece of the recipient's DNA by means of RecA proteins**. This involves breakage and reunion of paired DNA segments as seen in (see Fig. 1).



Transformation is summarized in Figs. 2A through 2D of the following Slideshow Activity below.

Slideshow Activity

Flash animation showing transformation in bacteria.
Copyright © Gary E. Kaiser
html5 version of animation for iPad showing transformation in bacteria.
<p>Transformation is a form of genetic recombination in which a DNA fragment from a dead, degraded bacterium enters a competent recipient bacterium and is exchanged for a piece of DNA of the recipient. Transformation usually involves only homologous recombination, a recombination of homologous DNA regions having nearly the same nucleotide sequences. Typically this involves similar bacterial strains or strains of the same bacterial species.</p> <p>During transformation, DNA fragments (usually about 10 genes long) are released from a dead degraded bacterium and bind to DNA binding proteins on the surface of a competent living recipient bacterium. Depending on the bacterium, either both strands of DNA penetrate the recipient, or a nuclease degrades one strand of the fragment and the remaining DNA strand enters the recipient. This DNA fragment from the donor is then exchanged for a piece of the recipient's DNA by means of RecA proteins and other molecules and involves breakage and reunion of the paired DNA segments.</p>

Concept Map for Horizontal Gene Transfer

Transduction

Transduction involves the transfer of a **DNA fragment from one bacterium to another by a bacteriophage**. There are two forms of transduction: generalized transduction and specialized transduction.

a. Generalized transduction

During the replication of a **lytic bacteriophage and temperate bacteriophages**, the phage **capsid sometimes accidentally assembles around a small fragment of bacterial DNA**. When this bacteriophage, or transducing particle, infects another bacterium, it **injects the fragment of donor bacterial DNA it is carrying into the recipient where it can subsequently be exchanged for a piece of the recipient's DNA** by homologous recombination. Generalized transduction is summarized in Fig. 3A through 3G. Generalized transduction occurs in a variety of bacteria, including *Staphylococcus*, *Escherichia*, *Salmonella*, and *Pseudomonas*.

Plasmids, such as the penicillinase plasmid of *Staphylococcus aureus*, **may also be carried from one bacterium to another by generalized transduction**.

For more information: Review of the lytic life cycle of lytic bacteriophages.

Generalized transduction is summarized in Figs. 3A through 3G of the following Slideshow Activity below.

Slideshow Activity

Flash animation showing generalized transduction.
Copyright © Gary E. Kaiser
Flash animation showing generalized transduction.
<p>During the replication of lytic bacteriophages and temperate bacteriophages, occasionally the phage capsid accidentally assembles around a small fragment of bacterial DNA. When this bacteriophage, called a transducing particle, infects another bacterium, it injects the fragment of donor bacterial DNA it is carrying into the recipient where it can subsequently be exchanged for a piece of the recipient's DNA by homologous recombination. Generalized transduction occurs in a variety of bacteria, including <i>Staphylococcus</i>, <i>Escherichia</i>, <i>Salmonella</i>, and <i>Pseudomonas</i>.</p>

b. Specialized transduction

Specialized transduction may occur occasionally during the **lysogenic life cycle of a temperate bacteriophage**. During spontaneous induction, **a small piece of bacterial DNA may sometimes be exchanged for a piece of the bacteriophage genome**, which remains in the bacterial nucleoid. **This piece of bacterial DNA replicates as a part of the bacteriophage genome and is put into each phage capsid**. The bacteriophages are released, adsorb to recipient

bacteria, and **inject the donor bacterium DNA/phage DNA complex into the recipient bacterium where it inserts into its chromosome.**

For more information: Review of the lysogenic life cycle of temperate bacteriophages.

Specialized transduction is summarized in Figs. 4A through 4F of the following Slideshow Activity below.

Slideshow Activity

Flash animation showing specialized transduction.
Copyright © Gary E. Kaiser
html5 version of animation for iPad showing specialized transduction.
Specialized transduction occurs occasionally during the lysogenic life cycle of a temperate bacteriophage. During spontaneous induction, a small piece of bacterial DNA may sometimes be exchanged for a piece of the bacteriophage genome, which remains in the bacterial chromosome. This piece of bacterial DNA replicates as a part of the bacteriophage genome and is put into each phage capsid. The bacteriophages are released, adsorb to recipient bacteria, and inject the donor bacterium DNA/phage DNA complex into the recipient bacterium where it inserts into its nucleoid.

Concept Map for Horizontal Gene Transfer

Self Check



Conjugation

Conjugation is a **transfer of DNA from a living donor bacterium to a living recipient bacterium by cell-to-cell contact**. In **Gram-negative bacteria it typically involves a conjugation or sex pilus.**

Conjugation is encoded by plasmids or transposons. **It involves a donor bacterium that contains a conjugative plasmid and a recipient cell that does not.** A conjugative plasmid **is self-transmissible**, in that it possesses all the necessary genes for that plasmid to transmit itself to another bacterium by conjugation. Conjugation genes known as ***tra* genes** enable the bacterium to **form a mating pair with another organism**, while ***oriT*(origin of transfer) sequences determine where on the plasmid DNA transfer is initiated** by serving as the replication start site where DNA replication enzymes will nick the DNA to initiate DNA replication and transfer. In addition, **mobilizable plasmids** that lack the *tra* genes for self-transmissibility but possess the *oriT* sequences for initiation of DNA transfer may also be transferred by conjugation if the bacterium containing them also possesses a conjugative plasmid. The *tra* genes of the conjugative plasmid enable a mating pair to form, while the *oriT* of the mobilizable plasmid enable the DNA to move through the conjugative bridge (**See Fig. 5**).

Fig. 5: Transfer of Mobilizable Plasmids During Conjugation
Copyright © Gary E. Kaiser
Mobilizable plasmids, that lack the <i>tra</i> genes for self-transmissibility but possess the <i>oriT</i> sequences for initiation of DNA transfer, may also be transferred by conjugation if the bacterium containing them also possesses a conjugative plasmid. The <i>tra</i> genes of the conjugative plasmid enable a mating pair to form while the <i>oriT</i> sequences of the mobilizable plasmid enables the DNA to move through the conjugative bridge.

Transposons ("jumping genes") are small pieces of DNA that encode enzymes that enable the transposon to **move from one DNA location to another, either on the same molecule of DNA or on a different molecule**. Transposons may be found as part of a bacterium's chromosome (conjugative transposons) or in plasmids and are usually between one and twelve genes long. A transposon contains a number of genes, such as those coding for antibiotic resistance or other traits, flanked at both ends by insertion sequences coding for an enzyme called transposase. Transposase is the enzyme that catalyzes the cutting and resealing of the DNA during transposition.

For more information: Review of plasmids and transposons.

Flash animation illustrating transposons.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating transposons.

Transposons (transposable elements or "jumping genes" are small pieces of DNA that encode enzymes that transpose the transposon, that is, move it from one DNA location to another, either on the same molecule of DNA or on a different molecule. A transposon contains a number of genes, coding for antibiotic resistance or other traits, flanked at both ends by insertion sequences coding for an enzyme called transposase. Transposase is the enzyme that catalyzes the cutting and resealing of the DNA during transposition. Thus, such transposons are able to cut themselves out of a bacterial chromosome or a plasmid and insert themselves into another chromosome or plasmid and contribute in the transmission of antibiotic resistance among a population of bacteria.

Conjugative transposons, like conjugative plasmids, **carry the genes that enable mating pairs to form for conjugation**. Therefore, conjugative transposons also enable mobilizable plasmids and nonconjugative transposons to be transferred to a recipient bacterium during conjugation.

Many conjugative plasmids and conjugative transposons possess rather **promiscuous transfer systems that enable them to transfer DNA not only to like species, but also to unrelated species**. The ability of bacteria to adapt to new environments as a part of bacterial evolution most frequently results from the acquisition of large DNA sequences from another bacterium by conjugation.

a. Transfer of conjugative plasmids by conjugation in Gram-negative bacteria

In Gram-negative bacteria, the first step in conjugation involves a **conjugation pilus** (sex pilus or F pilus) **on the donor bacterium binding to a recipient bacterium** lacking a conjugation pilus. Typically the conjugation **pilus retracts** or depolymerizes **pulling the two bacteria together**. A series of **membrane proteins coded for by the conjugative plasmid then forms a bridge and an opening between the two bacteria**, now called a **mating pair**.

Using the rolling circle model of DNA replication, **a nuclease breaks one strand of the plasmid DNA** at the origin of transfer site (*oriT*) of the plasmid **and that nicked strand enters the recipient bacterium**. The other strand remains behind in the donor cell. **Both the donor and the recipient plasmid strands then make a complementary copy of themselves**. Both bacteria now possess the conjugative plasmid.

For more information: Review of pili.

This process is summarized in Figs 6A through 6F of the following Slideshow Activity below.

Slideshow Activity

Flash animation showing transfer of conjugative plasmids by conjugation in Gram-negative bacteria.

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing transfer of conjugative plasmids by conjugation in Gram-negative bacteria.

Conjugation involves a donor bacterium that contains a conjugative plasmid and a recipient cell that does not. A conjugative plasmid is self-transmissible, in that it possesses all the necessary genes for that plasmid to transmit itself to another bacterium by conjugation. Conjugation genes known as *tra* genes enable the bacterium to form a mating pair with another organism, while *oriT* (origin of transfer) sequences determine where on the plasmid DNA transfer is initiated by serving as the replication start site where DNA replication enzymes will nick the DNA to initiate DNA replication and transfer. In addition, mobilizable plasmids that lack the *tra* genes for self-transmissibility but possess the *oriT* for initiation of DNA transfer may also be transferred by conjugation if the bacterium containing them also possesses a conjugative plasmid. The *tra* genes of the conjugative plasmid enable a mating pair to form and the *oriT* of the mobilizable plasmid enable the DNA to replicate as it moves through the conjugative bridge.

This is the mechanism by which **resistance plasmids (R-plasmids)**, **coding for multiple antibiotic resistance and conjugation pilus formation**, are

transferred from a donor bacterium to a recipient. This is a big problem in treating opportunistic gram-negative infections such as urinary tract infections, wound infections, pneumonia, and septicemia by such organisms as *E. coli*, *Proteus*, *Klebsiella*, *Enterobacter*, *Serratia*, and *Pseudomonas*, as well as with intestinal infections by organisms like *Salmonella* and *Shigella*.

Flash animation showing transfer of R-plasmids by conjugation in Gram-negative bacteria.
Copyright © Gary E. Kaiser
html5 version of animation for iPad showing transfer of R-plasmids by conjugation in Gram-negative bacteria.
R plasmids are conjugative plasmids coding for mating pair formation and also multiple antibiotic resistance. A conjugative plasmid is self-transmissible, in that it possesses all the necessary genes for that plasmid to transmit itself to another bacterium by conjugation. Conjugation genes known as <i>tra</i> genes enable the bacterium to form a mating pair with another organism, while <i>oriT</i> (origin of transfer) genes determine where on the plasmid DNA transfer is initiated. The plasmid also possess genes coding for resistance to a number of different antibiotics.

There is also evidence that the conjugation pilus may also serve as a direct channel through which single-stranded DNA may be transferred during conjugation.

b. F⁺ conjugation

F⁺ conjugation results in the transfer of an **F⁺ plasmid** possessing *tra* genes coding only for a conjugation pilus and mating pair formation from a donor bacterium to a recipient bacterium. **One strand of the F⁺ plasmid is broken with a nuclease** at the origin of transfer (*oriT*) sequence that determines where on the plasmid DNA transfer is initiated by serving as the replication start site where DNA replication enzymes will nick the DNA to initiate DNA replication and transfer. **The nicked strand enters the recipient bacterium while the other plasmid strand remains in the donor.** Each strand then makes a complementary copy. **The recipient then becomes an F⁺ male and can make a sex pilus.**

F⁺ conjugation is shown in Fig.7A through 7F of the following Slideshow Activity below.

Slideshow Activity

Flash animation showing F⁺ conjugation.
Copyright © Gary E. Kaiser
html5 version of animation for iPad showing F+ conjugation.
F ⁺ conjugation involves a donor bacterium that contains a conjugative plasmid known as an F ⁺ plasmid and a recipient cell that does not. A conjugative plasmid is self-transmissible, in that it possesses all the necessary genes for that plasmid to transmit itself to another bacterium by conjugation. Conjugation genes known as <i>tra</i> genes enable the bacterium to form a mating pair with another organism, while <i>oriT</i> (origin of transfer) genes determine where on the plasmid DNA transfer is initiated. The F ⁺ plasmid codes only for formation of a conjugation pilus. Mobilizable plasmids, however, that lack the <i>tra</i> genes for self-transmissibility but possess the <i>oriT</i> genes for initiation of DNA transfer may also be transferred by conjugation if the bacterium containing them also possesses a conjugative plasmid. The <i>tra</i> genes of the conjugative plasmid enable a mating pair to form and the <i>oriT</i> genes of the mobilizable plasmid enable the DNA to moves through the conjugative bridge.

In addition, **mobilizable plasmids** that lack the *tra* genes for self-transmissibility but possess the *oriT* sequences for initiation of DNA transfer may also be transferred by conjugation. The *tra* genes of the F⁺ plasmid enables a mating pair to form and the *oriT* sequences of the mobilizable plasmid enables the DNA to moves through the conjugative bridge (**See Fig. 5 above**).

c. Hfr (high frequency recombinant) conjugation

Hfr conjugation begins when an **F⁺ plasmid** with *tra* genes coding for mating pair formation **inserts or integrates into the nucleoid to form an Hfr bacterium.** **A nuclease then breaks one strand of the donor's DNA** at the origin of transfer (*oriT*) location of the inserted F⁺ plasmid and **the nicked strand of the donor DNA begins to enter the recipient bacterium.** The remaining non-nicked DNA strand remains in the donor and makes a complementary copy of itself.

The bacterial connection usually breaks before the transfer of the entire chromosome is completed so the remainder of the F⁺ plasmid seldom enters the recipient. As a result, **there is a transfer of some chromosomal DNA**, which may be exchanged for a piece of the recipient's DNA through homologous recombination, **but not the ability to form a conjugation pilus and mating pairs.**

Hfr conjugation is shown in Fig. 8A through 8E in the following Slideshow Activity below.

Slideshow Activity

Flash animation showing Hfr conjugation in bacteria.
Copyright © Gary E. Kaiser
html5 version of animation for iPad showing Hfr conjugation in bacteria.
Hfr recombination begins when an F+ plasmid with tra genes coding for mating pair formation inserts or

integrates into the chromosome to form an Hfr bacterium. A nuclease then breaks one strand of the donor's DNA at the origin of transfer (oriT) location of the inserted F+ plasmid and the nicked strand of the donor DNA begins to enter the recipient bacterium. The remaining non-nicked DNA strand remains in the donor and makes a complementary copy of itself. The bacterial connection usually breaks before the transfer of the entire chromosome is completed so the remainder of the F+ plasmid seldom enters the recipient. As a result, there is a transfer of some chromosomal DNA, which may be exchanged for a piece of the recipient's DNA through homologous recombination, but not the ability to form a conjugation pilus and mating pairs.

Class activity

Watch University of Texas at San Antonio microbiologist Karl Klose discusses the problem of antibiotic resistance in a 2013 TED talk.

Use your notes to name and describe the bacterial mechanisms of horizontal gene transfer referred to in this talk as "funeral grab," "viral pass," and "making whoopee."

TPS Questions

Concept Map for Horizontal Gene Transfer

Quiz Group



Self Quiz for Horizontal Gene Transfer

Quiz Group



Back to Unit 2 Table of Contents

Back to Softchalk Lessons Table of Contents

single-celled organism behavior in order to find a new sight to colonize.

13. Quorum sensing enables bacteria to communicate with members of their own species, with other species of bacteria, and with their eukaryotic host cells.

14. Most genes coding for virulence factors in bacteria are located in pathogenicity islands or PAIs and are usually acquired by horizontal gene transfer.

15. Many bacteria involved in infection have the ability to co-opt the functions of the host cell for the bacterium's own benefit by producing secretions systems that enable the bacterium to directly inject bacterial effector molecules into the cytoplasm of the host cell in order to alter the host cell's cellular machinery, cellular function, or cellular communication.

Common Course Objectives

1. Relate quorum sensing gene expression to the population of bacteria and how this can relate to bacterial pathogenicity.
2. Describe pathogenicity islands and how they are primarily transferred from one bacterium to another.
3. Describe how bacterial secretion systems can influence the ability of a bacterium to influence the action of other bacteria or of eukaryotic cells.
4. Describe mechanisms of how a normally communalistic bacterium can become pathogenic.

Detailed Learning Objectives

1*. Define the following:

- a. pathogenicity
- b. virulence

2**. Define and briefly describe the overall process of quorum sensing in bacteria and how it may enable bacteria to behave as a multicellular population.

3*. State at least two possible advantages of individual bacterial behavior.

4*. State at least two possible advantages of multicellular bacterial behavior.

5. State what is meant by intraspecies, interspecies, and interkingdom communication.

6*. State the function of bacterial secretions systems (injectosomes) such as the type 3 and type 6 secretion systems in bacterial pathogenicity.

(*) = Common theme throughout the course

(**) = More depth and common theme

TPS Questions

Bacterial Quorum Sensing


In this Learning Object we are going to look at several aspects of bacterial genetics that are directly related to bacterial pathogenicity, namely, quorum sensing, pathogenicity islands, and secretion systems. Pathogenicity and virulence are terms that refer to an organism's ability to cause disease. **Pathogenicity** is the ability of a microbe to cause disease and inflict damage upon its host, whereas **virulence** is the degree of pathogenicity within a group or species of microbes as indicated by case fatality rates and/or the ability of the organism to invade the tissues of the host. The pathogenicity of an organism, that is its ability to cause disease, is determined by its **virulence factors**.

Many of the virulence factors that enable bacteria to colonize the body and/or harm the body are the products of quorum sensing genes. Many bacteria are able to **sense their own population density, communicate with each other by way of secreted chemical factors, and behave as a population rather than as individual bacteria**. This plays an important role in pathogenicity and survival for many bacteria.

Bacteria can behave either as individual single-celled organisms or as multicellular populations. Bacteria exhibit these behaviors by chemically "talking" to one another through a process called quorum sensing. **Quorum sensing involves the production, release, and community-wide sensing of molecules called autoinducers that modulate gene expression, and ultimately bacterial behavior, in response to the density of a bacterial population.**

To initiate the process of quorum sensing, bacterial genes code for the **production of signaling molecules called autoinducers** that are released into the bacterium's surrounding environment. These signaling molecules then **bind to signaling receptors** either on the bacterial surface or in the cytoplasm. When these autoinducers reach a critical, threshold level, they **activate bacterial quorum sensing genes that enable the bacteria to behave as a multicellular population**

rather than as individual single-celled organisms (see Fig. 1). The autoinducer/receptor complex is able to bind to DNA promoters and activate the transcription of quorum sensing-controlled genes in the bacterium. In this way, individual bacteria within a group are able to benefit from the activity of the entire group.



Flash animation showing quorum sensing with a low density and a high density of bacteria.

Copyright © Gary E. Kaiser

html5 version of animation showing quorum sensing with a low density and a high density of bacteria.

At a low density of bacteria, the signaling molecules (autoinducers) diffuse away from the bacteria. Sufficient quantities of these molecules are unavailable for binding to the signaling receptors on the bacterial surface and the quorum sensing genes that enable the bacteria to act as a population are not activated. The bacterium then utilizes genes that enable the bacterium to act as an individual organism rather than as a multicellular population. Acting as individual organisms may better enable that low density of bacteria to gain a better foothold in their new environment.


At a high density of bacteria, sufficient quantities of signaling molecules (autoinducers) are available for binding to the signaling receptors on the bacterial surface and the quorum sensing genes that enable the bacteria to act as a population become activated. The outcomes of bacteria-host interaction are often related to bacterial population density. Bacterial virulence, that is its ability to cause disease, is largely based on the bacterium's ability to produce gene products called virulence factors that enable that bacterium to colonize the host, resist body defenses, and harm the body.

1. In Gram-negative bacteria, the autoinducers are typically molecules called **acyl-homoserine lactones or AHL**. AHLs diffuse readily out of and into bacterial cells where they bind to AHL receptors in the cytoplasm of the bacteria. When a critical level of AHL is reached, the cytoplasmic autoinducer/receptor complex functions as a DNA-binding transcriptional activator.

2. In Gram-positive bacteria, the autoinducers are **oligopeptides**, short peptides typically 8-10 amino acids long. Oligopeptides cannot diffuse in and out of bacteria like AHLs, but rather leave bacteria via specific exporters. They then bind to autoinducer receptors on the surface of the bacterium. When a critical level of oligopeptide is reached, the binding of the oligopeptide to its receptor starts a phosphorylation cascade that activates DNA-binding transcriptional regulatory proteins called response regulators.

The outcomes of bacteria-host interaction are often related to bacterial population density. Bacterial virulence, that is its ability to cause disease, is largely based on the bacterium's ability to produce gene products called **virulence factors** that enable that bacterium to colonize the host, resist body defenses, and harm the body.

A. At a **low density of bacteria**, the autoinducers diffuse away from the bacteria (see Fig. 2). Sufficient quantities of these molecules are unable to bind to the signaling receptors on the bacterial surface and the **quorum sensing genes that enable the bacteria to act as a population are not activated**. This enables the bacteria to **behave as individual, single-celled organisms**.



Possible advantages of individual bacterial behavior seen at low bacterial density: Producing virulence factors that better enable them to colonize the body.

If a relatively small number of a specific bacterium were to enter the body and immediately start producing their virulence factors, chances are the body's immune systems would have sufficient time to recognize and counter those virulence factors and remove the bacteria before there was sufficient quantity to cause harm. The bacterium instead **utilizes genes that enable it to act as an individual organism** rather than as part of a multicellular population.

Acting as individual organisms may better enable that low density of bacteria to **gain a better foothold** in their new environment in the following ways:



1. Many bacteria are capable of **motility** and motility serves to keep bacteria in an optimum environment via **taxis**.

Motility and chemotaxis probably help some intestinal and urinary pathogens to **move through the mucous layer so they can attach to the epithelial cells of the mucous membranes**. In fact, many bacteria that can colonize the mucous membranes of the bladder and the intestines are motile. Motility probably helps these bacteria move through the mucus in places where it is less viscous.

Flash animation showing a motile bacterium contacting a host cell by swimming through the mucus.
Copyright © Gary E. Kaiser
html5 version of animation for iPad showing a motile bacterium contacting a host cell by swimming through the mucus.
The mucosal surfaces of the bladder and the intestines constantly flush bacteria away in order to prevent colonization. Motile bacteria that can swim chemotactically toward mucosal surfaces may have a better chance to make contact with the mucous membranes, attach, and colonize. Many bacteria that can colonize the mucous membranes of the bladder and the intestines are motile. Motility probably helps these bacteria move through the mucus in places where it is less viscous.

<p>Movie of swimming <i>Escherichia coli</i> as seen with phase contrast microscopy</p> <p>Courtesy of Dr. Howard C. Berg from the Roland Institute at Harvard.</p>	<p>Movie of motile <i>Escherichia coli</i> with fluorescent-labelled flagella</p> <p>Courtesy of Dr. Howard C. Berg from the Roland Institute at Harvard.</p>
--	--

2. One of the body's innate defenses is the ability to physically remove bacteria from the body through such means as the constant shedding of surface epithelial cells from the skin and mucous membranes, the removal of bacteria by such means as coughing, sneezing, vomiting, and diarrhea, and bacterial removal by bodily fluids such as saliva, blood, mucous, and urine. **Bacteria may resist this physical removal by producing pili (see Fig. 3), cell wall adhesins proteins (see Fig. 4), and/or biofilm-producing capsules.** Some pili, called **type IV pili** also **allow some bacteria to "walk" or "crawl" along surfaces** to spread out and eventually form microcolonies.

<p>Fig. 3: Adhesive Tip of Bacterial Pili</p>	<p>Fig. 4: Bacterial Adhesins</p>
 <p>The diagram shows a pink, spherical bacterium with numerous thin, hair-like pili extending from its surface. One pili is shown in detail, ending in a small, rounded adhesive tip. This tip is bound to a red, Y-shaped receptor molecule embedded in the yellow surface of a host cell.</p>	 <p>The diagram shows a red, rod-shaped bacterium with a layer of purple, oval-shaped adhesins on its surface. These adhesins are bound to orange, Y-shaped receptor molecules embedded in the orange surface of a host cell membrane.</p>
<p>Copyright © Gary E. Kaiser</p>	<p>Surface proteins called adhesins in the bacterial cell wall bind to receptor molecules on the surface of a susceptible host cell enabling the bacterium to make intimate contact with the host cell, adhere, colonize, and resist flushing.</p> <p>Copyright © Gary E. Kaiser</p>

<p>Flash animation showing a bacterium using adhesins to adhere to a host cell.</p>
<p>Copyright © Gary E. Kaiser</p>
<p>html5 version of animation for iPad showing a bacterium using adhesins to adhere to a host cell.</p>
<p>Surface proteins called adhesins in the bacterial cell wall bind to receptor molecules on the surface of a susceptible host cell enabling the bacterium to make intimate contact with the host cell, adhere, colonize, and resist flushing.</p>

<p>Flash animation showing a bacterium using both pili and adhesins to adhere to a host cell.</p>
<p>Copyright © Gary E. Kaiser</p>
<p>html5 version of animation for iPad showing a bacterium using both pili and adhesins to adhere to a host cell.</p>
<p>Pili enable some organisms to adhere to receptors on target host cells. The pilus has a shaft composed of a protein called pilin. At the end of the shaft is the adhesive tip structure having a shape corresponding to that of specific glycoprotein or glycolipid receptors on a host cell. Because both the bacteria and the host cells have a negative charge, pili may enable the bacteria to bind to host cells without initially having to get close enough to be pushed away by electrostatic repulsion. Once attached to the host cell, the pili can depolymerize and this enables bacterial cell wall adhesins to bind to adhesin receptors on the host cell. This allows the bacterial cell wall to make more intimate contact with the host cell and enables the bacterium to colonize the host cell and resist flushing. There is also evidence that the binding of pili to host cell receptors can serve as a trigger for activating the synthesis of some cell wall adhesins.</p>


<p>Movie of twitching motility of <i>Pseudomonas</i></p>
<p>Courtesy of Dr. Howard C. Berg from the Roland Institute at Harvard</p>

Scanning electron micrograph E. coli with pili; courtesy of Dennis Kunkel's Microscopy.

3. Many bacteria secrete an **extracellular polysaccharide or polypeptide matrix** called a **capsule or glycocalyx** that enables the bacteria to adhere to host cells, resist phagocytosis, and form microcolonies.

As the bacteria geometrically increase in number by binary fission, so does the amount of their secreted autoinducers, and production of high levels of autoinducers then enables the population of bacteria to communicate with one another by quorum sensing.

At a high density of bacteria, large quantities of autoinducers are produced (see Fig. 5) and are able to bind to the signaling receptors on the bacterial surface in sufficient quantity so as to activate the quorum sensing genes that enable the bacteria to **behave as a multicellular population** (see Fig. 1 above).



Animation of the molecular cascade during bacterial quorum sensing.


Courtesy of HHMI's Biointeractive.

Advantages of multicellular behavior seen at high bacterial density: Better enabling the bacterial population to persist in the body.


1. **By behaving as a multicellular population, individual bacteria within a group are able to benefit from the activity of the entire group.** As the entire population of bacteria simultaneously turn on their virulence genes, the body's immune systems are much less likely to have enough time to counter those virulence factors before harm is done.
2. This triggers production of an **extracellular adhesive matrix (glycocalyx)** enabling the bacteria to form **microcolonies** and irreversibly attachment to the mucous membranes. **Biofilm formation begins.**
3. Virulence factors such as exoenzymes and toxins can **damage host cells enabling the bacteria in the biofilm to obtain nutrients.** The **biofilm continues to develop and mature.**
4. As the area becomes over-populated with bacteria, **quorum sensing enables some of the bacteria to escape the biofilm, often by again producing flagella, and return to individual single-celled organism behavior** in order to find a new sight to colonize.

Pseudomonas aeruginosa is an example of a quorum sensing bacterium. *P. aeruginosa* causes severe hospital-acquired infections, chronic infections in people with cystic fibrosis, and potentially fatal infections in those who are immunocompromised.


1. When *P. aeruginosa* first enters the body, they are at a **low density of bacteria**. The autoinducers diffuse away from the bacteria (see Fig. 2 above), sufficient quantities of these molecules are unable to bind to the signaling receptors, and the quorum sensing genes that enable the bacteria to act as a population are not activated. The *P. aeruginosa* continue to **function as individual bacteria**. **Motility genes** (coding for flagella) and **adhesin genes** (coding for pili and cell wall adhesins) **are expressed**. The **flagella** enable the initial bacteria to swim through mucus towards host tissues such as mucous membranes. **Pili** then enable the bacteria to reversibly attach to host cells in order to resist flushing and begin colonization (See Fig. 6A). **Type IV pili**, which enable a twitching motility in some bacteria, then enable the bacteria as they replicate to crawl along and spread out over the mucous membranes (See Fig. 6B). The pili subsequently retract and bacterial **cell wall adhesins** enable a more intimate attachment of the bacterium to the mucous membranes (See Fig. 6C).




Planktonic *Pseudomonas aeruginosa* use their polar flagella and chemotaxis to swim towards host mucous membranes. Pili then bind to host cell receptors for initial but reversible bacterial attachment.




As the bacteria begin to replicate, type IV pili enable the bacteria, by way of twitching motility, to crawl along the surface of the mucous membranes and spread out.






The pili retract and bacterial cell wall adhesins enable a more intimate attachment of the bacterium.

2. Once *P. aeruginosa* has colonized, it is able to replicate geometrically and achieve a high population density. Quorum sensing genes are activated and the bacteria **function as a population**. This triggers production of an extracellular polysaccharide called alginate to **form microcolonies** and enables irreversible attachment to the mucous membranes (**See Fig. 6D**). **Biofilm formation begins.**



As the bacteria replicate, quorum sensing genes trigger production of an extracellular polysaccharide called alginate to form microcolonies and enable irreversible attachment to the mucous membranes. Biofilm formation begins.

3. Quorum sensing genes coding for **enzymes and toxins that damage host cells** are produced. These are injected into the host cells by way of an **injectosome**. This releases **nutrients for the bacteria in the biofilm**. The bacteria continue to replicate as the biofilm continues to develop, mushroom up, and mature (**See Fig. 6E**).




Copyright © Gary E. Kaiser

Quorum sensing genes coding for enzymes and toxins that damage host cells are produced. This releases nutrients for the bacteria in the biofilm. The bacteria continue to replicate as the biofilm continues to develop, mushroom up, and mature.

4. As the bacteria replicate, the **biofilm continues to mature (See Fig. 6F)**. **Water channels form** within the biofilm to deliver water, oxygen, and nutrients to the growing population of *P. aeruginosa*. The high density of bacteria bacteria are now **acting as a multicellular population** rather than as individual bacteria.

Fig. 6F: Development of a Biofilm by *Pseudomonas aeruginosa*: Step 6



Copyright © Gary E. Kaiser

As the bacteria replicate, the biofilm continues to mature. Water channels form within the biofilm to deliver water, oxygen, and nutrients to the growing population of *P. aeruginosa*.


Electron micrograph of a biofilm of *Haemophilus influenzae* from Biomedcentral.com

The biofilm enables bacteria to:

- a. resist attack by antibiotics;
- b. trap nutrients for bacterial growth and remain in a favorable niche;
- c. adhere to environmental surfaces and resist flushing;
- d. live in close association and communicate with other bacteria in the biofilm; and
- e. resist phagocytosis and attack by the body's complement pathways.

5. When the population of *P. aeruginosa* begins to **outgrow their local environment**, quorum sensing enables them to **turn off adhesin genes and turn on flagella genes** that allow some of the bacteria to **spread out of the biofilm to new location** within that environment via motility (**See Fig. 6G and Fig. 6H**).


Fig. 6G: Development of a Biofilm by *Pseudomonas aeruginosa*: Step 7



Copyright © Gary E. Kaiser

As the population begins to overgrow the area and nutrients become limited, quorum sensing genes trigger some of the *P. aeruginosa* in the biofilm to again produce flagella.

Fig. 6H: Development of a Biofilm by *Pseudomonas aeruginosa*: Step 8




Copyright © Gary E. Kaiser

Planktonic *P. aeruginosa* leave the biofilm and move to a new location to begin new biofilms.

It turns out that bacteria are **multilingual**. They use quorum sensing not only to "talk" to members their own species (**intraspecies communication**), but also to "talk" to bacteria that are not of their genus and species (**interspecies communication**). Intraspecies autoinducers and receptors enable bacteria to communicate with others of their own species while interspecies autoinducers and receptors enable bacteria to communicate with bacteria of a different species or genus (see Fig. 7). The autoinducers for interspecies communications are referred to as **AI-2 family autoinducers** and are different from the intraspecies (AI-1) autoinducers. **In some cases bacteria use interspecies communication to work cooperatively with various other bacteria in their biofilm to the benefit all involved; in other cases, bacteria may use interspecies communication in such a way that one group benefits at the expense of another.**

Fig. 7: Intraspecies and Interspecies Communication



Copyright © Gary E. Kaiser

Intraspecies autoinducers and receptors enable bacteria to communicate with others of their own species while interspecies autoinducers and receptors enable bacteria to communicate with bacteria of a different species or genus.

Furthermore, bacteria are capable of **interkingdom communication**, communication between bacteria and their animal or plant host. Increasing numbers of bacteria are being found that **have signaling receptors that recognize human hormones**. For example, a number of bacteria that are pathogens of the human intestinal tract have a sensing molecule called QseC that binds the human hormones adrenaline and noradrenaline. This, in turn, **activates various virulence genes of the bacteria**. On the other hand, **some bacterial autoinducers can enter human host cells and regulate human cellular function**. For example, at low concentration some bacterial autoinducers suppress host immune responses thus better enabling those bacteria to better establish themselves in the body. At high concentrations, however, they stimulate an inflammatory response in the host to help the bacteria to spread from the initial infection site. One bacterial autoinducer has been found to initiate apoptosis (cell suicide) in phagocytes such as neutrophils and macrophages.

Quiz Group



Concept Map for Bacterial Quorum Sensing, Pathogenicity Islands, and Secretion Systems

Pathogenicity Islands

The genomes of **pathogenic bacteria**, when compared with those of similar nonpathogenic species or strains, often **show extra genes coding for virulence factors**, that is, **molecules expressed and secreted by the bacterium that enable them to colonize the host, evade or inhibit the immune responses of the host, enter into or out of a host cell, and/or obtain nutrition from the host**. These include virulence factors such as capsules, adhesins, type 3 secretion systems, invasins, and toxins.

Most genes coding for virulence factors in bacteria are **located in pathogenicity islands or PAIs** and are usually acquired by **horizontal gene transfer**. These PAIs may be located in the bacterial chromosome, in plasmids, or even in bacteriophage genomes that have entered the bacterium. The genomes of most pathogenic bacteria typically contain multiple PAIs that can account for up to 10 - 20% of the bacterium's genome. PAIs carry genes such as transposases, integrases, or insertion sequences that enable them to insert into host bacterial DNA. Transfer RNA (tRNA) genes are often the target site for integration of PAIs. **Conjugative plasmids** are the most frequent means of transfer of PAIs from one bacterium to another and the transfer of PAIs **can then confer virulence to a previously nonpathogenic bacterium**.

Self Check




Concept Map for Bacterial Quorum Sensing, Pathogenicity Islands, and Secretion Systems


Type 3 Secretion Systems (T3SS or Injectisomes) and Type 6 Secretion Systems (T6SS)

Many bacteria involved in infection have the ability to **co-opt the functions of host cells for the bacterium's own benefit**. This is done by way of bacterial secretions systems that enable the bacterium to **directly inject bacterial effector molecules into the cytoplasm of the host cell in order to alter its cellular machinery or cellular communication** to the benefit of the bacteria.

The most common type is the **type 3 secretion system or T3SS (see Fig. 8)**. A secretion apparatus in the cytoplasmic membrane and cell wall of the bacterium polymerizes a hollow needle that is lowered to the cytoplasmic membrane of the host cell and a translocon protein is then delivered to anchor the needle to the host cell. Effector proteins in the bacterium can now be injected into the cytoplasm of the host cell. The delivery system is sometimes called an injectisome. (A type 4 secretion system can transfer effector proteins and/or DNA into the host cell because it is similar to the conjugation transfer system initiated by *tra* genes discussed under horizontal gene transfer.)

Fig. 8: The Bacterial Type 3 Secretion System





Article, Illustrations, and electron micrographs of injectisomes from the MarlovitsLab.

Electron micrograph of an injectisome from Wikipedia.

Some bacteria, such as *Pseudomonas aeruginosa* and *Vibrio cholerae*, produce a **type 6 secretion system**, or **T6SS**, that consists of a protein tube surrounded by a contractile sheath, similar to the tail of T4-bacteriophages. (A bacteriophage is a virus that only infects bacteria.) **The type 6 secretion system not only injects effector molecules into eukaryotic cells, but also is able to inject antibacterial effector molecules into other bacteria in order to kill those bacteria.** Predator bacteria can use their T6SS to kill prey bacteria. In fact, *V. cholerae* and *P. aeruginosa* have been shown to "duel" with one another via their respective T6SSs.

Concept map for Introduction to Pathogenesis and Quorum Sensing

***V. cholerae* also uses its T6SS to promote horizontal gene transfer by way of transformation.** Individual *V. cholerae* cells also use their T6SS to attack one another upon cell-to-cell contact. Most members of the population, however, produce immunity proteins that protect them from being killed by the effector molecules that are injected. Not all strains of *V. cholerae* in the population, however, produce these immunity proteins and these non-immune cells are subsequently lysed, releasing their DNA into the environment. This DNA can then be taken up by neighboring competent *V. cholerae* via transformation.

For more information: Review of Horizontal Gene Transfer

TPS Questions

iBiology YouTube Lecture on Microbial Pathogenicity

Self Check



Concept Map for Bacterial Quorum Sensing, Pathogenicity Islands, and Secretion Systems

Self Quiz for Quorum Sensing, Pathogenicity Islands, and Secretion Systems

Quiz Group



[Back to Unit 2 Table of Contents](#)

[Back to Softchalk Lessons Table of Contents](#)

now bind and initiate transcription

12. Bacteria also use translational control of enzyme synthesis. One method is for the bacteria to produce noncoding RNA (ncRNA) molecules that are complementary to the mRNA coding for the enzyme, and when the small RNA binds to the mRNA by complementary base pairing, ribosomes cannot attach to the mRNA, the mRNA is not transcribed and translated into protein, and the enzyme is not made. In bacteria, these ncRNAs are often called small RNAs (sRNAs).

13. Feedback inhibition controls the activity of the enzyme rather than its synthesis and can be noncompetitive or competitive.

14. In the case of non-competitive inhibition, the inhibitor is the end product of a metabolic pathway that is able to bind the allosteric site on the enzyme. Binding of the inhibitor to the allosteric site alters the shape of the enzyme's active site thus preventing binding of the first substrate in the metabolic pathway. In this way, the pathway is turned off.

15. In the case of what is called competitive inhibition, the inhibitor is the end product of an enzymatic reaction. That end product is also capable of reacting with the enzyme's active site and prevents the enzyme from binding its normal substrate. As a result, the end product is no longer synthesized.

Common Course Objectives

1. Compare and contrast the genetic control of enzyme activity (enzyme synthesis) in bacteria with the control of enzyme activity through feedback inhibition.
2. Compare and contrast an inducible operon with a repressible operon and give an example of each.
3. Compare and contrast competitive inhibition with noncompetitive inhibition.

Detailed Learning Objectives

1. Compare and contrast the genetic control of enzyme activity (enzyme synthesis) in bacteria with the control of enzyme activity through feedback inhibition.
2. Compare and contrast an inducible operon with a repressible operon and give an example of each.
3. Compare how the presence or absence of tryptophan affects the *trp* operon.
4. Compare how the presence or absence of lactose affects the *lac* operon.
5. Compare how the presence or absence of an inducer affects activators.
6. Briefly describe how small RNAs can regulate enzyme activity.
7. Define the following:
 - a. repressor
 - b. inducer
 - c. activator
 - d. enhancer
 - e. small RNAs
8. Compare and contrast competitive inhibition with noncompetitive inhibition.

TPS Questions

In living cells, there are hundreds of different enzymes working together in a coordinated manner. **Living cells neither synthesize nor break down more material than is required for normal metabolism and growth.** All of this necessitates precise **control mechanisms** for turning metabolic reactions on and off.

There is tremendous diversity in the mechanisms bacteria use to regulate enzyme synthesis and enzyme activity. For pretty much every step between the activation of a gene and the final enzyme reaction from that gene product there is some bacterial mechanism for regulation that step. Here we will look at several well studied examples.

1. Genetic Control of Enzyme Synthesis through Repression, Induction, or Enhancement of Transcription

Genetic control of enzyme activity refers to **controlling transcription of the mRNA needed for an enzyme's synthesis.** In prokaryotic cells, this involves the **induction, repression, or enhancement of enzyme synthesis by regulatory proteins that can bind to DNA and either induce, block, or enhance the function of RNA polymerase,** the enzyme required for transcription. The regulatory proteins are often part of either an operon or a regulon. An **operon** is a set of genes transcribed as a polycistronic message that is collectively controlled by a regulatory protein. A **regulon** is a set of related genes controlled by the same regulatory protein but transcribed as monocistronic units. **Regulatory proteins may function either as repressors, activators, or enhancers.**

For more information: Review of transcription

a. Repressors

Repressors are regulatory proteins that **block transcription of mRNA**. They do this by binding to a portion of DNA called the **operator** (operators are often called boxes now) that lies downstream of a promoter. The binding of the regulatory protein to the operator **prevents RNA polymerase from binding to the operator and transcribing the coding sequence for the enzymes**. This is called **negative control** and is mostly seen in biosynthetic reactions where a bacterium only makes a molecule like a particular amino acid when that amino acid is not present in the cell.

Repressors are allosteric proteins that have a binding site for a specific molecule. Binding of that molecule to the allosteric site of the repressor can alter the repressor's shape that, in turn affects its ability to bind to DNA. This can work in one of two ways:

1. **Some repressors are synthesized in a form that cannot by itself bind to the operator.** This is referred to as a **repressible system**. The binding of a molecule called a **corepressor**, however, alters the shape of the regulatory protein to a form that can bind to the operator and subsequently block transcription.

An example of this type of repressible system is the ***trp* operon** in *Escherichia coli* that encodes the five enzymes in the pathway for the biosynthesis of the amino acid tryptophan. In this case, **the repressor protein coded for by the *trp* regulatory gene, normally does not bind to the operator region of the *trp* operon and the five enzymes needed to synthesize the amino acid tryptophan are made (see Slideshow Figs. 1A and B).**

Slideshow Activity

Flash animation of the repressible <i>trp</i> operon in the absence of a corepressor.
Copyright © Gary E. Kaiser
html5 version of animation for iPad illustrating the repressible <i>trp</i> operon in the absence of a corepressor.
<p>If tryptophan is not present in the <i>E. coli</i>, the enzymes required for tryptophan synthesis need to be made. In the absence of tryptophan (the corepressor), the bacterium produces an inactive repressor protein that is unable to bind to the operator of the <i>trp</i> operon. This allows RNA polymerase, which binds to the promoter region of the operon located ahead of the operator region, to transcribe the <i>trp</i> operon structural genes <i>trpE</i>, <i>trpD</i>, <i>trpC</i>, <i>trpB</i>, and <i>trpA</i> that code for the enzymes that enable the bacterium to synthesize tryptophan.</p> <p>TrpE and TrpD are the two subunits for making anthranilate synthetase, the enzyme that catalyzes the first two reactions in the tryptophan pathway.</p> <p>TrpC is is indole glycerolphosphate synthetase, the enzyme that catalyzes the next two steps in the pathway.</p> <p>TrpB and TrpA are subunits for making tryptophan synthetase. the enzyme that catalyzes the synthesis of tryptophan from indole-glycerol phosphate and serine.</p>


Tryptophan, the end product of these enzyme reactions, however, **functions as a corepressor**. Once sufficient tryptophan has been synthesized, the cell needs to terminate its synthesis. The tryptophan is able to bind to a site on the allosteric repressor protein, changing its shape and enabling it to interact with the *trp* operator region. **Once the repressor binds to the operator, RNA polymerase is unable to bind to the promoter and transcribe the genes for tryptophan biosynthesis.** Therefore, **when sufficient tryptophan is present, transcription of the enzymes that allows for its biosynthesis are turned off (see Slideshow Figs. 2A and 2B).**


Slideshow Activity

Flash animation of the repressible <i>trp</i> operon in the presence of a corepressor.
Copyright © Gary E. Kaiser
html5 version of animation for iPad illustrating the repressible <i>trp</i> operon in the presence of a corepressor.
<p>If tryptophan, the corepressor, is present in the <i>E. coli</i>, the enzymes required for tryptophan synthesis do not need to be made. In the presence of tryptophan, the bacterium produces an active repressor protein that is able to bind to the operator of the <i>trp</i> operon. This prevents RNA polymerase from binding to the promoter region of the operon located ahead of the operator region, and the 5 structural genes (<i>trpE</i>, <i>trpD</i>, <i>trpC</i>, <i>trpB</i>, and <i>trpA</i>) that code for enzymes that enable the bacterium to synthesize the amino acid tryptophan are not transcribed and translated.</p>

In addition to repression, the expression of the *trp* operon is also regulated by **attenuation**. The *trpL* gene codes for a mRNA leader sequence that controls operon expression through attenuation. This leader sequence mRNA consists of domains 1, 2, 3, and 4. Domain 3 can base pair with either domain 2 or domain 4.


At **high tryptophan concentrations**, domains 3 and 4 pair in such a way as to form stem and loop structures that block the transcription of the remainder of the leader sequence mRNA and subsequently, the transcription of the structural genes for tryptophan biosynthesis (see Fig. 3A).





When excess tryptophan is available, there is a rapid translation of the early *trp* leader mRNA enabling domain 2 to pair with domain 1 and form a pause loop. The ribosome pauses at a stop codon (arrow) causing domain 3 to pair with domain 4 and form a terminator loop. Transcription of the remainder of the *trp* operon is terminated. Rapid initial translation is able to occur with excess tryptophan present because there is a sufficient quantity of Trp tRNA available to translate the two Trp codons (asterisks).

However, at **low concentrations of tryptophan**, domains 3 and 2 pair. This pairing allows for the full transcription of the leader sequence mRNA, as well as that of the structural genes for tryptophan biosynthesis (**see Fig. 3B**).



When tryptophan is limited, there is a slow translation of the early *trp* leader mRNA which enables domain 2 to pair with domain 3 and form an antiterminator loop. Transcription of the remainder of the *trp* operon continues and the enzymes required for tryptophan synthesis are made. Slow initial translation is able to occur with low levels of tryptophan present because there is limited Trp tRNA available to translate the two Trp codons (asterisks) causing the ribosome to stall at the Trp codons and enabling domain 2 to pair with domain 3 rather than domain 1.

2. Other repressors are synthesized in a form that readily binds to the operator and blocks transcription. However, the binding of a molecule called an **inducer** alters the shape of the regulatory protein in a way that now blocks its binding to the operator and thus permits transcription. This is referred to as an **inducible system**.

An example of an inducible system is the ***lac* operon** that encodes for the three enzymes needed for the degradation of lactose by *Escherichia coli*. *E. coli* will only synthesize the enzymes it requires to utilize lactose if that sugar is present in the surrounding environment. In this case, **lactose functions as an inducer**. In the **absence of lactose**, the **active repressor protein binds to the operator** and **RNA polymerase is unable to bind to the promoter and transcribe the genes for utilization of lactose**. As a result, the enzymes needed for the utilization of lactose are not synthesized (**see Slideshow Figs. 4A and 4B**).



Flash animation of the inducible *lac* operon in the absence of the inducer lactose.

Copyright © Gary E. Kaiser

html5 version of animation for iPad of the inducible *lac* operon in the absence of the inducer lactose.

If lactose is unavailable in the environment for the *E. coli* to use as an energy source, there is no need to produce the enzymes required for lactose utilization. In the absence of lactose (the inducer), the bacterium produces an active repressor protein that binds to the operator of the *lac* operon. This prevents RNA polymerase from binding to the promoter region of the operon located ahead of the operator region and transcribing the *lac* operon structural genes that enable the bacterium to utilize lactose.

When **lactose, the inducer, is present, a metabolite of lactose called allolactose binds to the allosteric repressor protein and causes it to change shape in such a way that it is no longer able to bind to the operator.** Now RNA polymerase is able to transcribe the three *lac* operon structural genes and the bacterium is able to synthesize the enzymes required for the utilization of lactose (see Slideshow Figs. 5A and 5B).

Slideshow
Activity

Flash animation of the inducible *lac* operon in the presence of the inducer lactose.

Copyright © Gary E. Kaiser

html5 version of animation for iPad of the inducible *lac* operon in the presence of the inducer lactose.

If lactose is available in the environment for the *E. coli* to use as an energy source, there is a need to produce the enzymes required for lactose utilization. In the presence of lactose (the inducer), a metabolite of lactose called allolactose (a combination of glucose and galactose). The allolactose binds to the active repressor protein rendering it inactive and no longer able to bind to the operator of the *lac* operon. This allows RNA polymerase, which binds to the promoter region of the operon located ahead of the operator region, to reach and transcribe the *lac* operon structural genes that enable the bacterium to utilize lactose. The *lacX* gene codes for LacX, a beta-galactosidase enzyme that splits the disaccharide lactose into glucose and galactose. The *lacY* gene codes for LacY, a beta-galactoside permease that functions as a symporter to pump lactose into the bacterium. The *lacA* gene codes for LacA, a transacetylase. Its function in lactose catabolism, if any, is uncertain.

Concept Map for Bacterial Enzyme Regulation

TPS Questions

Quiz Group

b. Activators

Activators are regulatory proteins that promote transcription of mRNA. Activators control genes that have a promoter to which RNA polymerase cannot bind. The promoter lies adjacent to a segment of DNA called the **activator-binding site.** The **activator is an allosteric protein synthesized in a form that cannot normally bind to the activator-binding site.** As a result, **RNA polymerase is unable to bind to the promoter and transcribe the genes** (see Slideshow Fig. 6).

Slideshow
Activity

Flash animation of an activator in the absence of an inducer.

Copyright © Gary E. Kaiser

html5 version of animation for iPad of an activator in the absence of an inducer.

Activators are regulatory proteins that promote transcription of mRNA. Activators control genes that have a promoter to which RNA polymerase cannot bind. The promoter lies adjacent to a segment of DNA called the activator-binding site. The activator is an allosteric protein synthesized in a form that cannot normally bind to the activator-binding site. As a result, RNA polymerase is unable to bind to the promoter and transcribe the structural gene and the enzyme is not made.

However, **binding of a molecule called an inducer to the activator alters the shape of the activator in a way that now allows it to bind to the activator-binding site.** The binding of the activator to the activator-binding site, in turn, **enables RNA polymerase to bind to the promoter and initiate transcription** (see Slideshow Figs. 7A and 7B). This is called **positive control** and is mostly seen in catabolic reactions where a bacterium only makes enzymes for the

catabolism of a substrate when that substrate is available to the cell.

Slideshow
Activity

Flash animation of an activator in the presence of an inducer.

Copyright © Gary E. Kaiser

html5 version of animation for iPad of an activator in the presence of an inducer.

Binding of a molecule called an inducer to the inactive activator alters the shape of the activator in a way that now allows it to bind to the activator-binding site. The binding of the activator to the activator-binding site, in turn, enables RNA polymerase to bind to the promoter and initiate transcription of the structural gene and the enzyme is made.


Concept Map for Bacterial Enzyme Regulation

Quiz Group

c. Enhancers

Enhancers are regulatory proteins that bind to DNA located some distance from the operon they control by working with DNA-binding proteins. The DNA-binding proteins bend the DNA in a way that now allows the enhancer to interact with the promoter in such a way that RNA polymerase can now bind and initiate transcription (see Fig. 8).

Fig. 8: Enhancers and DNA-Bending Proteins Initiating Transcription



Copyright © Gary E. Kaiser

Enhancers are regulatory proteins that bind to DNA located some distance from the operon they control by working with DNA-binding proteins. The DNA-binding proteins bend the DNA in a way that now allows the enhancer to interact with the promoter in such a way that RNA polymerase can now bind and initiate transcription.

2. Genetic Control of Enzyme Synthesis through Promoter Recognition and through DNA Supercoiling

a. Promoter Recognition

The specific sigma factors that bind to RNA polymerase determine which operon will be transcribed.


b. DNA Supercoiling

DNA supercoiling can change the tertiary shape of a DNA molecule from its normal form to one that has a left-handed twist called Z-DNA. The activities of some promoters are decreased with Z-DNA while others are increased.

3. Genetic Control of Enzyme Synthesis through the Translational Control of Enzyme Synthesis

a. RNA interference (RNAi)

RNA interference (RNAi) is a process whereby small non-coding regulatory RNAs (ncRNAs) such as microRNAs (miRNAs) regulate gene expression. These **ncRNAs** are regulatory molecules **that are complementary to an early portion of the 5' end of the mRNA coding for the enzyme**. When the small RNA binds to the mRNA by complementary base pairing, **ribosomes cannot attach to the mRNA blocking its translation**. As a result, the enzyme is not made (**see Fig. 9**). In bacteria these ncRNAs are often called small RNAs (sRNAs); in animal cells, plant cells, and viruses they are often called microRNAs (miRNA).



b. Ribosomal Proteins (r-proteins)

Ribosomal proteins bind to rRNA to form ribosomal subunits. Because the nucleotide base sequence for the mRNA coding for the r-proteins has similarities to that of the rRNA to which that r-protein binds during subunit formation, r-proteins not yet incorporated into ribosomal subunits can bind to that mRNA and block translation.

For more information: Review of translation


Concept Map for Bacterial Enzyme Regulation


4. Controlling the Enzyme's Activity (Feedback Inhibition).

Enzyme activity can be controlled by competitive inhibition and non-competitive inhibition.

a. Non-competitive Inhibition

With what is termed **non-competitive inhibition**, the inhibitor is the end product of a metabolic pathway that is able to bind to a second site (the **allosteric site** on the enzyme. Binding of the inhibitor to the allosteric site **alters the shape of the enzyme's active site** thus preventing binding of the first substrate in the metabolic pathway. In this way, the pathway is turned off (**see Fig. 10**).





Flash animation showing non-competitive antagonism in the absence of an inhibitor.

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing non-competitive antagonism in the absence of an inhibitor.

During an allosteric enzyme reaction in the absence of an inhibitor, a specific substrate binds to the active site of the bacterial enzyme forming an enzyme-substrate complex. The enzyme then catalyzes the breakdown of the substrate into two end products required by the bacterium.

Flash animation showing non-competitive antagonism in the presence of an inhibitor.


Copyright © Gary E. Kaiser


html5 version of animation for iPad showing non-competitive antagonism in the presence of an inhibitor.

When the end product (inhibitor) of a pathway combines with the allosteric site of the enzyme, this alters the active site of the enzyme so it can no longer bind to the starting substrate of the pathway. This blocks production of the end product.

b. Competitive Inhibition

In the case of what is called **competitive inhibition**, the inhibitor is the end product of an enzymatic reaction. **That end product is also capable of reacting with the enzyme's active site and prevents the enzyme from binding its normal substrate.** As a result, the end product is no longer synthesized (see Fig. 11).





The end product (inhibitor) of a pathway binds to the active site of the first enzyme in the pathway. As a result, the enzyme can no longer bind to the starting substrate of the pathway.

Flash animation showing competitive inhibition.

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing competitive antagonism.

Competitive inhibition is a process whereby an inhibitor chemically resembles a substrate in a metabolic pathway. Because of their similarity, either the inhibitor or the substrate can bind to the substrate's enzyme. When the bacterial enzyme binds to its normal substrate, an enzyme-substrate complex forms and the end products required by that bacterium are made. When the enzyme is bound to the inhibitor, it is unable to bind to its natural substrate and that blocks the production of the end products of that metabolic pathway. If enough inhibitor is present in the bacterium, all of the bacterial enzyme - which is normally present in the cell only in limited amounts - is tied up with the inhibitor and the end products needed for the bacterium's metabolism are not produced

For more information: Review of enzymes

Quiz Group

Self Quiz for Enzyme Regulation

Quiz Group

Back to Unit 2 Table of Contents

Back to Softchalk Lessons Table of Contents

An Overview to the Control of Microorganisms

AN OVERVIEW OF THE CONTROL OF MICROORGANISMS

Fundamental Statements for this Learning Object:

- 1. Physical control includes such methods of control as high or low temperature, desiccation, osmotic pressure, radiation, and filtration.**
- 2. Chemical control refers to the use of disinfectants, antiseptics, antibiotics, and chemotherapeutic antimicrobial chemicals.**
- 3. Sterilization is the process of destroying all living organisms and viruses.**
- 4. Disinfection is the elimination of microorganisms, but not necessarily endospores, from inanimate objects or surfaces.**
- 5. Decontamination is the treatment of an object or inanimate surface to make it safe to handle.**
- 6. A disinfectant is an agent used to disinfect inanimate objects but generally is toxic to use on human tissues.**
- 7. An antiseptic is an agent that kills or inhibits growth of microbes but is safe to use on human tissue.**
- 8. A sanitizer is an agent that reduces microbial numbers to a safe level.**
- 9. An antibiotic is a metabolic product produced by one microorganism that inhibits or kills other microorganisms.**
- 10. Synthetic chemicals that can be used therapeutically.**
- 11. An agent that is cidal in action kills microorganisms.**
- 12. An agent that is static in action inhibits the growth of microorganisms.**
- 13. Selective toxicity means that the chemical being used should inhibit or kill the intended pathogen without seriously harming the host.**
- 14. A broad spectrum agent is one generally effective against a variety of Gram-positive and Gram-negative bacteria.**
- 15. A narrow spectrum agent generally works against just Gram-positives, Gram-negatives, or only a few bacteria.**

Common Course Objectives

1. Define terms used in describing the methods of microbial control.
2. Identify appropriate methods of microbial control under a given specific circumstance.
3. Recall the advantages and disadvantages of the different types of chemical control.

Detailed Learning Objectives

1. Define the following:

- a*. selective toxicity
- b*. broad spectrum antibiotic
- c*. narrow spectrum antibiotic
- d*. antibiotic
- e*. chemotherapeutic synthetic drug
- f*. cidal
- g*. static
- h*. sterilization
- i*. disinfection
- j*. disinfectant
- k*. antiseptic
- l*. physical agent

(*) = Common theme throughout the course

AN OVERVIEW TO THE CONTROL OF MICROORGANISMS

Control of microorganisms is essential in order to prevent the transmission of diseases and infection, stop decomposition and spoilage, and prevent unwanted microbial contamination. Microorganisms are controlled by means of physical agents and chemical agents. **Physical agents** include such methods of control as high or low temperature, desiccation, osmotic pressure, radiation, and filtration. Control by **chemical agents** refers to the use of disinfectants, antiseptics, antibiotics, and chemotherapeutic antimicrobial chemicals.

Basic terms used in discussing the control of microorganisms include:

1. Sterilization

Sterilization is the process of destroying all living organisms and viruses. A sterile object is one free of all life forms, including bacterial endospores, as well as viruses.

2. Disinfection

Disinfection is the elimination of microorganisms, but not necessarily endospores, from inanimate objects or surfaces.

3. Decontamination

Decontamination is the treatment of an object or inanimate surface to make it safe to handle.

4. Disinfectant

A disinfectant is an agent used to disinfect inanimate objects but generally too toxic to use on human tissues.

5. Antiseptic

An antiseptic is an agent that kills or inhibits growth of microbes but is safe to use on human tissue.

6. Sanitizer

A sanitizer is an agent that reduces microbial numbers to a safe level.

7. Antibiotic

An antibiotic is a metabolic product produced by one microorganism that inhibits or kills other microorganisms.

8. Chemotherapeutic synthetic drugs

Synthetic chemicals that can be used therapeutically.

9. Cidal

An agent that is cidal in action will kill microorganisms and viruses.

10. Static

An agent that is static in action will inhibit the growth of microorganisms.

In this lesson we will concentrate on the chemical control of microbial growth with a special emphasis on the antibiotics and chemotherapeutic antimicrobial chemicals used in treating bacterial infections. Control of microorganisms by means of physical agents will be covered in Lab 18 and control by means of disinfectants, antiseptics, and sanitizers will be discussed in Lab 19.

For more information: Preview of control of microorganisms by means of physical agents from Lab 18.

For more information: Preview of control of microorganisms by means of chemical agents from Lab 19.

The basis of chemotherapeutic control of bacteria is selective toxicity. **Selective toxicity** means that the chemical being used should inhibit or kill the intended pathogen without seriously harming the host. A **broad spectrum** agent is one generally effective against a variety of Gram-positive and Gram-negative bacteria; a **narrow spectrum** agent generally works against just Gram-positives, Gram-negatives, or only a few bacteria.

As mentioned above, such agents may be cidal or static in their action. A cidal agent kills the organism while a static agent inhibits the organism's growth long enough for body defenses to remove it.

There are two categories of antimicrobial chemotherapeutic agents: antibiotics and synthetic drugs. Antibiotics are metabolic products of one microorganism that inhibit or kill other microorganisms. Chemotherapeutic synthetic drugs are antimicrobial drugs synthesized by chemical procedures in the laboratory. Many of today's antibiotics are now actually semisynthetic and some are even made synthetically.

As mentioned above, antibiotics are metabolic products of one microorganism that inhibit or kill other microorganisms. Why then do bacteria produce antibiotics? There is growing support for multiple actions for microbial antibiotic production:

- If produced in large enough amounts, antibiotics may be used as a weapon to inhibit or kill other microbes in the vicinity to reduce competition for food.
- Antibiotics produced in sublethal quantities may function as interspecies quorum sensing molecules enabling a number of different bacteria to form within a common biofilm where metabolic end products of one organism may serve as a substrate for another. All the organisms are protected within the same biofilm.
- Antibiotics produced in sublethal quantities may function as interspecies quorum sensing molecules enabling some bacteria to manipulate others to become motile and swim away thus reducing the competition for food.
- Antibiotics action may result in the degradation of bacterial cell walls or DNA and these products can act as cues that trigger other bacteria to produce a protective biofilm.
- Antibiotics produced in sublethal quantities may trigger intraspecies quorum sensing. Exposure to low concentrations of an antibiotic may trigger bacteria to produce quorum sensing molecules that trigger the population to produce a protective biofilm. The biofilm then protects the population from greater concentrations of the antibiotic.

In the following Softchalk lessons we will now look at the two sides of the story with regards to controlling bacterial infections by means of chemicals:

1. Ways in Which Our Control Agents May Affect Bacteria

2. Ways in Which Bacteria May Resist Our Control Agents

Self Quiz for Ways in which Our Chemical Control Agents may Affect Bacteria


Quiz Group



[Back to Unit 2 Table of Contents](#)

[Back to Softchalk Lessons Table of Contents](#)

Ways in which Our Chemical Control Agents may Affect Bacteria



Fundamental Statements for this Softchalk Lesson:

1. Many antibiotics (penicillins, cephalosporins, vancomycin, bacitracin) inhibit normal synthesis of peptidoglycan by bacteria and cause osmotic lysis. They do this by inactivating the enzymes or the transporters involved in peptidoglycan synthesis.
2. A few antimicrobial chemotherapeutic agents (INH, ethambutol) inhibit normal synthesis of the acid-fast cell wall.
3. A very few antibiotics (polymyxin, colistin, daptomycin) alter the bacterial cytoplasmic membrane causing leakage of molecules and enzymes needed for normal bacterial metabolism.
4. Some antimicrobial chemotherapeutic agents (fluoroquinolones, sulfonamides, trimethoprim) inhibit normal nucleic acid replication in bacteria.
5. Many antibiotics (tetracyclines, macrolides, oxazolidinones, streptogramins) alter bacterial ribosomes, interfering with translation of mRNA into proteins and thereby causing faulty protein synthesis.
6. There are 2 common antimicrobial modes of action for disinfectants, antiseptics, and sanitizers: damaging the lipids and/or proteins of the semipermeable cytoplasmic membrane of microorganisms resulting in leakage of cellular materials; and denaturing microbial enzymes and other proteins.
7. A number of factors which influence the antimicrobial action of disinfectants and antiseptics, including the concentration of the chemical agent, the temperature at which the agent is being used, the kinds of microorganisms present, the number of microorganisms present, and the nature of the material bearing the microorganisms.
8. Endospore producers such as *Bacillus* species, *Clostridium* species, and acid-fast bacteria like *Mycobacterium tuberculosis* are harder to eliminate.

Common Course Objectives

1. Define terms used in describing the methods of microbial control.
2. Recall the mechanism of action for each class of chemotherapeutic chemical agent and give specific examples for each class.
3. Identify appropriate methods of microbial control under a given specific circumstance.
4. Recall the advantages and disadvantages of the different types of chemical control.
5. Identify clinically appropriate methods of growth inhibition when given a specific microbe

Detailed Learning Objectives

1**. Describe 6 different ways antibiotics or disinfectants may affect bacterial structures or macromolecules and state how each ultimately causes harm to the cell.

2*. State which of the following groups of antibiotics: 1) inhibit peptidoglycan synthesis; 2) inhibit nucleic acid synthesis; 3) alter bacterial 30S ribosomal subunits blocking translation; or 4) alter bacterial 50S ribosomal subunits blocking translation.

- a. macrolides (erythromycin, azithromycin, clarithromycin, dirithromycin, troleandomycin, etc.), oxazolidinones (linezolid), and streptogramins
- b. penicillins, monobactams, carbapenems, cephalosporins, and vancomycin
- c. fluoroquinolones (norfloxacin, lomefloxacin, fleroxacin, ciprofloxacin, enoxacin, trovafloxacin, etc.), sulfonamides and trimethoprim, and metronidazole
- d. aminoglycosides (streptomycin, neomycin, netilmicin, tobramycin, gentamicin, amikacin, etc.) and tetracyclines (tetracycline, doxycycline, demeclocycline, minocycline, etc.)

(*) = Common theme throughout the course

(**) = More depth and common theme

TPS Questions

Ways in which Our Chemical Control Agents may Affect Bacteria

1. Many Antibiotics Inhibit Normal Synthesis of Peptidoglycan by Bacteria and Cause Osmotic Lysis.

Common Antibacterial Antibiotics

As learned earlier, in order for bacteria to increase their size following binary fission, links in the peptidoglycan must be broken, new peptidoglycan monomers must be inserted into the growing cell wall, and the peptide cross links must be resealed.

New peptidoglycan synthesis occurs at the cell division plane by way of a collection of cell division machinery known as the divisome. The following sequence of events occur at the divisome:

1. Bacterial enzymes called **autolysins**:

- a) Break the glycosidic bonds between the peptidoglycan monomers at the point of growth along the existing peptidoglycan; and
- b) Break the peptide cross-bridges that link the rows of sugars together (**see Slideshow Fig. 1, steps 1-3 below**).

Slideshow Activity

2. The **bactoprenols** transport the peptidoglycan monomers across the cytoplasmic membrane and insert the monomers into existing peptidoglycan (**see Slideshow Fig. 2, steps 1-6 below**).

Slideshow Activity

3. **Transglycosylase** enzymes then insert and link new peptidoglycan monomers into the breaks in the peptidoglycan (**see Slideshow Fig. 3, steps 1-2 below**).

Slideshow Activity


4. Finally, **transpeptidase** enzymes reform the peptide cross-links between the rows and layers of peptidoglycan to make the wall strong (**see Slideshow Fig. 4, steps 1-2 below**).

Slideshow Activity

Flash animation illustrating the synthesis of peptidoglycan


For more information: Peptidoglycan

Interference with this process results in the formation of a weak cell wall and osmotic lysis of the bacterium. Agents that inhibit peptidoglycan synthesis include the **penicillins** (penicillin G, methicillin, oxacillin, ampicillin, amoxicillin, ticarcillin, etc.), the **cephalosporins** (cephalothin, cefazolin, cefoxitin, cefotaxime, cefaclor, cefoperazone, cefixime, ceftriaxone, cefuroxime, etc.), the **carbapenems** (imipenem, meropenem), the **monobactams** (aztreonam), and the carbacephems (loracarbef). Penicillins, monobactams, carbapenems, and cephalosporins are known chemically as beta-lactam antibiotics because they all share a molecular structure called a beta-lactam ring (**see Fig. 5**). The **glycopeptides** (vancomycin, teichoplanin) and lipopeptides (daptomycin) also inhibit peptidoglycan synthesis.



a. Beta-lactam antibiotics such as penicillins and cephalosporins

Penicillins, cephalosporins, as well as other beta-lactam antibiotics, bind to the transpeptidase enzymes (also called penicillin-binding proteins) responsible for reforming the peptide cross-links between rows and layers of peptidoglycan of the cell wall as new peptidoglycan monomers are added during bacterial cell growth. This binding **blocks the transpeptidase enzymes from cross-linking the sugar chains and results in a weak cell wall**. In addition, these antibiotics appear to interfere with the bacterial controls that keep autolysins in check, with resulting degradation of the peptidoglycan and osmotic lysis of the bacterium (**see Fig. 6**).



Copyright © Gary E. Kaiser

During normal bacterial growth, bacterial enzymes called autolysins put breaks in the peptidoglycan in order to allow for insertion of new peptidoglycan monomers consisting of NAG, NAM, and a pentapeptide. As new monomers are linked to the existing rows of peptidoglycan during cell wall synthesis, transpeptidase enzymes (also called penicillin-binding proteins) form a peptide bridge that cross-links the peptides coming off of each NAM. These links connect each row of sugars with its adjacent rows and each layer of peptidoglycan with its adjacent layers. This is what gives peptidoglycan its strength.

Flash animation illustrating how penicillins inhibit peptidoglycan synthesis.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating how penicillins inhibit peptidoglycan synthesis.

During normal bacterial growth, bacterial enzymes called autolysins put breaks in the peptidoglycan in order to allow for insertion of new peptidoglycan monomers consisting of NAG, NAM, and a pentapeptide. As new monomers are linked to the existing rows of peptidoglycan during cell wall synthesis, transpeptidase enzymes (also called penicillin-binding proteins) form a peptide bridge that cross-links the peptides coming off of each NAM. These links connect each row of sugars with its adjacent rows and each layer of peptidoglycan with its adjacent layers. This is what gives peptidoglycan its strength.

Penicillins, cephalosporins, and other beta-lactam antibiotics resemble the two terminal amino acids of the monomer's pentapeptide (D-Ala-D-Ala) to which transpeptidases normally bind. By binding to and tying up the active site of the transpeptidases, these antibiotics block the formation of the peptide cross-links. This results in a weak cell wall and osmotic lysis of the bacterium.


Flash animation showing how penicillins inhibit peptidoglycan synthesis.

© Juliet V. Spencer, Stephanie K.M. Wong, authors, Licensed for use, ASM MicrobeLibrary.

b. Glycopeptides

Glycopeptides such as vancomycin and the lipoglycopeptide teichoplanin bind to the D-Ala-D-Ala portion of the pentapeptides of the peptidoglycan monomers and block the formation of glycosidic bonds between the sugars by the transglycosidase enzymes, as well as the formation of the peptide cross-links by the transpeptidase enzymes. This results in a weak cell wall and subsequent osmotic lysis of the bacterium (see Fig. 7).

Fig. 7: The Role of Vancomycin in Blocking Transpeptidase Enzymes from Assembling the Peptide Cross-Links in Peptidoglycan



Copyright © Gary E. Kaiser

During normal bacterial growth, bacterial enzymes called autolysins put breaks in the peptidoglycan in order to allow for insertion of new peptidoglycan monomers - consisting of NAG, NAM, and a pentapeptide. These

monomers are then attached to the growing end of the bacterial cell wall with transglycosidase enzymes. Finally, transpeptidase enzymes (also called penicillin-binding proteins) form a peptide bridge that cross-links the peptides coming off of each NAM. These links connect each row of sugars with its adjacent rows and each layer of peptidoglycan with its adjacent layers. This is what gives peptidoglycan its strength.

Vancomycins bind to the two terminal amino acids of the monomer's pentapeptide (D-Ala-D-Ala). This binding prevents the transpeptidase enzymes from forming the peptide cross-links between the rows and layers of peptidoglycan. (As a result of steric hindrance, not shown here, vancomycin may also interfere with the formation of the glycosidic bonds between the sugars of the peptidoglycan monomers and those in the existing cell wall). This results in a weak cell wall and subsequent osmotic lysis of the bacterium.

Flash animation illustrating how vancomycin inhibits peptidoglycan synthesis.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating how vancomycin inhibits peptidoglycan synthesis.

During normal bacterial growth, bacterial enzymes called autolysins put breaks in the peptidoglycan in order to allow for insertion of new peptidoglycan monomers - consisting of NAG, NAM, and a pentapeptide. These monomers are then attached to the growing end of the bacterial cell wall with transglycosidase enzymes. Finally, transpeptidase enzymes (also called penicillin-binding proteins) form a peptide bridge that cross-links the peptides coming off of each NAM. These links connect each row of sugars with its adjacent rows and each layer of peptidoglycan with its adjacent layers. This is what gives peptidoglycan its strength.

Vancomycins bind to the two terminal amino acids of the monomer's pentapeptide (D-Ala-D-Ala). This binding prevents the transpeptidase enzymes from forming the peptide cross-links between the rows and layers of peptidoglycan. (As a result of steric hindrance, not shown here, vancomycin may also interfere with the formation of the glycosidic bonds between the sugars of the peptidoglycan monomers and those in the existing cell wall). This results in a weak cell wall and subsequent osmotic lysis of the bacterium.


Flash animation showing how penicillins inhibit peptidoglycan synthesis.

© Juliet V. Spencer, Stephanie K.M. Wong, authors, Licensed for use, ASM MicrobeLibrary.

c. Bacitracin

Bacitracin binds to the transport protein bactoprenol after it inserts a peptidoglycan monomer into the growing cell wall. It subsequently prevents the dephosphorylation of the bactoprenol after it releases the monomer it has transported across the membrane. Bactoprenol molecules that have not lost the second phosphate group cannot assemble new monomers and transport them across the cytoplasmic membrane. As a result, no new monomers are inserted into the growing cell wall. As the autolysins continue to break the peptide cross-links and new cross-links fail to form, the bacterium bursts from osmotic lysis (**see Fig. 8**).

Fig. 8: The Role of Bacitracin in Blocking Peptidoglycan Synthesis



Copyright © Gary E. Kaiser

Peptidoglycan monomers - consisting of the sugars NAM and NAG with a pentapeptide coming off the NAM - are synthesized in the cytosol of the bacterium. These monomers are then transported across the cytoplasmic membrane and inserted into the growing peptidoglycan chain by membrane transporters called bactoprenols.

Bacitracin binds to bactoprenol after it inserts the peptidoglycan monomer it is transporting into the growing cell wall. It subsequently prevents the dephosphorylation of the bactoprenol. Bactoprenol molecules that have not lost the second phosphate group cannot assemble new monomers and transport them across the cytoplasmic

membrane. As a result, no new monomers are inserted into the growing cell wall. As the autolysins continue to break the peptide cross-links and new cross-links fail to form, the bacterium bursts from osmotic lysis.

Flash animation illustrating how bacitracin inhibits peptidoglycan synthesis.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating how bacitracin inhibits peptidoglycan synthesis.

Peptidoglycan monomers - consisting of the sugars NAM and NAG with a pentapeptide coming off the NAM - are synthesized in the cytosol of the bacterium. These monomers are then transported across the cytoplasmic membrane and inserted into the growing peptidoglycan chain by membrane transporters called bactoprenols.

Bacitracin binds to bactoprenol after it inserts the peptidoglycan monomer it is transporting into the growing cell wall. It subsequently prevents the dephosphorylation of the bactoprenol. Bactoprenol molecules that have not lost the second phosphate group cannot assemble new monomers and transport them across the cytoplasmic membrane. As a result, no new monomers are inserted into the growing cell wall. As the autolysins continue to break the peptide cross-links and new cross-links fail to form, the bacterium bursts from osmotic lysis.

Flash animation showing how penicillins inhibit peptidoglycan synthesis.

© Juliet V. Spencer, Stephanie K.M. Wong, authors, Licensed for use, ASM MicrobeLibrary.

Common Antibacterial Antibiotics

Concept map for Chemical Agents that Inhibit Cell Wall Synthesis, Alter the Cytoplasmic Membrane, or DNA Synthesis.

Self Check





2. A few Antimicrobial Chemotherapeutic Agents Inhibit Synthesis of the Acid-Fast Cell Wall

A few antimicrobial chemotherapeutic agents inhibit normal synthesis of the acid-fast cell wall of the genus *Mycobacterium*

1. INH (isoniazid) appears to block the synthesis of mycolic acid, a key component of the acid-fast cell wall of mycobacteria (see Fig. 9).
2. Ethambutol interferes with the synthesis of the outer membrane of acid-fast cell walls (see Fig. 9).

Fig. 9: Structure of an Acid-Fast Cell Wall





In addition to peptidoglycan, the acid-fast cell wall of *Mycobacterium* contains a large amount of glycolipids, especially mycolic acids. The peptidoglycan layer is linked to arabinogalactan (D-arabinose and D-galactose) which is then linked to high-molecular weight mycolic acids. The arabinogalactan/mycolic acid layer is overlaid with a layer of polypeptides and mycolic acids consisting of free lipids, glycolipids, and peptidoglycolipids. Other glycolipids include lipoarabinomannan and phosphatidylinositol mannosides (PIM). Like the outer membrane of the gram-negative cell wall, porins are required to transport small hydrophilic molecules through the outer membrane of the acid-fast cell wall.

Because of its unique cell wall, when it is stained by the acid-fast procedure, it will resist decolorization with acid-alcohol and stain red, the color of the initial stain, carbol fuchsin. With the exception of a very few other acid-fast bacteria such as *Nocardia*, all other bacteria will be decolorized and stain blue, the color of the methylene blue counterstain.

Common Antibacterial Antibiotics

Concept map for Chemical Agents that Inhibit Cell Wall Synthesis, Alter the Cytoplasmic Membrane, or Inhibit DNA Synthesis.

3. A very few Antibiotics Alter the Bacterial Cytoplasmic Membrane Causing Leakage of Molecules and Enzymes needed for Normal Bacterial Metabolism.

A very few antibiotics, such as polymyxins, colistins, and daptomycin, as well as many disinfectants and antiseptics, such as orthophenylphenol, chlorhexidine, hexachlorophene, zephiran, alcohol, and triclosans, **alter the bacterial cytoplasmic membrane causing leakage of molecules and enzymes needed for normal bacterial metabolism.**

- a. Polymyxins and colistins act as detergents and alter membrane permeability in Gram-negative bacteria. They cannot effectively diffuse through the thick peptidoglycan layer in gram-positives.
- b. Daptomycin disrupts the bacterial cytoplasmic membrane function by apparently binding to the membrane and causing rapid depolarization. This results on a loss of membrane potential and leads to inhibition of protein, DNA and RNA synthesis, resulting in bacterial cell death.
- c. Pyrazinamide inhibits fatty acid synthesis in the membranes of *Mycobacterium tuberculosis*.

For more information: Review of the bacterial cytoplasmic membrane

Common Antibacterial Antibiotics


Concept map for Chemical Agents that Inhibit Cell Wall Synthesis, Alter the Cytoplasmic Membrane, or Inhibit DNA Synthesis.

4. Some Antibiotics and Synthetic Drugs Inhibit Nucleic Acid Replication in Bacteria

a. The fluoroquinolones

Fluoroquinolones (norfloxacin, lomefloxacin, fleroxacin, ciprofloxacin, enoxacin, trovafloxacin, gatifloxacin, etc.) work by **inhibiting one or more of a group of enzymes called topoisomerases**, enzymes needed for supercoiling, replication, and separation of circular bacterial DNA (see Fig. 10). For example, DNA gyrase (topoisomerase II) catalyzes the negative supercoiling of the circular DNA found in bacteria. It is critical in bacterial DNA replication, DNA repair, transcription of DNA into RNA, and genetic recombination. Topoisomerase IV, on the other hand, is involved in the relaxation of the supercoiled circular DNA, enabling the separation of the interlinked daughter chromosomes at the end of bacterial DNA replication.

In Gram-negative bacteria, the main target for fluoroquinolones is DNA gyrase (topoisomerase II), an enzyme responsible for supercoiling of bacterial DNA during DNA replication; in Gram-positive bacteria, the primary target is topoisomerase IV, an enzyme responsible for relaxation of supercoiled circular DNA and separation of the inter-linked daughter chromosomes.

<p>Fig. 10: How an Antimicrobial Agent May Inactivate a Bacterial Enzyme</p>

<p>Copyright © Gary E. Kaiser</p>
<p>When an antibiotic binds to a bacterial enzyme, it may alter the activate site of the enzyme and prevent it from reacting with its substrate.</p>

<p>Flash animation illustrating a normal bacterial enzyme reaction.</p>
<p>Copyright © Gary E. Kaiser</p>
<p>html5 version of animation for iPad illustrating a normal bacterial enzyme reaction.</p>
<p>When an antibiotic binds to a bacterial enzyme, it may alter the activate site of the enzyme and prevent it from reacting with its substrate.</p>

<p>Flash animation illustrating how antimicrobial agents may inactivate a bacterial enzyme.</p>
<p>Copyright © Gary E. Kaiser</p>
<p>html5 version of animation for iPad illustrating how antimicrobial agents may inactivate a bacterial enzyme.</p>
<p>When an antibiotic binds to a bacterial enzyme, it may alter the activate site of the enzyme and prevent it from reacting with its substrate.</p>

For more information: [Review of the bacterial chromosome.](#)


Self Check




b. Sulfonamides

Sulfonamides (sulfamethoxazole, sulfanilamide) and **diaminopyrimidines** (trimethoprim) **block enzymes in the bacteria pathway required for the synthesis of tetrahydrofolic acid, a cofactor needed for bacteria to make the nucleotide bases thymine, guanine, uracil, and adenine** (see Fig. 11).

<p>Fig. 11: Pathway for the Synthesis of Tetrahydrofolic Acid, a Cofactor Needed for the Synthesis of DNA and RNA Nucleotides</p>
Content of Fig. 11 is missing from the page



This is done through a process called **competitive antagonism** whereby a drug chemically resembles a substrate in a metabolic pathway. Because of their similarity, either the drug or the substrate can bind to the substrate's enzyme. While the enzyme is bound to the drug, it is unable to bind to its natural substrate (see Fig. 12) and that blocks that step in the metabolic pathway. Typically, a sulfonamide and a diaminopyrimidine are combined. Co-trimoxazole, for example, is a combination of sulfamethoxazole and trimethoprim.



Flash animation illustrating competitive antagonism.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating competitive antagonism.

Competitive antagonism is a process whereby a drug chemically resembles a substrate in a metabolic pathway. Because of their similarity, either the drug or the substrate can bind to the substrate's enzyme. When the bacterial enzyme binds to its normal substrate, an enzyme-substrate complex forms and the end products required by that bacterium are made. When the enzyme is bound to the drug, it is unable to bind to its natural substrate and that blocks the production of the end products of that metabolic pathway. If enough drug is present in the bacterium, all of the bacterial enzyme - which is normally present in the cell only in limited amounts - is tied up with the drug and the end products needed for the bacterium's metabolism are not produced.

c. Metronidazole

Metronidazole is a drug that is activated by the microbial proteins flavodoxin and ferredoxin found in microaerophilic and anaerobic bacteria and certain protozoans. Once activated, the metronidazole **puts nicks in the microbial DNA strands**.

Concept map for Chemical Agents that Inhibit Cell Wall Synthesis, Alter the Cytoplasmic Membrane, or Inhibit DNA Synthesis.

Self Check



d. Rifampin (rifamycin)

Rifampin **blocks transcription** by inhibiting bacterial RNA polymerase, the enzyme responsible for transcription of DNA to mRNA.

For more information: Review of transcription

Concept map for Chemical Agents that Inhibit RNA Polymerase, Alter Prokaryotic Ribosomes, or Denature Enzymes

Common Antibacterial Antibiotics

5. Many Antibiotics Alter Bacterial Ribosomes, Interfering with Translation.

Many antibiotics **alter bacterial ribosomes**, interfering with translation of mRNA into proteins and thereby causing **faulty protein synthesis**. To learn more detail about the specific steps involved in translation during bacterial protein synthesis, see the animation that follows.

For more information: Review of bacterial ribosomes

For more information: Review of translation

Flash animation illustrating the early stages of translation during bacterial protein synthesis.

Copyright © Gary E. Kaiser


Codon Sheet

html5 version of animation for iPad illustrating the early stages of translation during bacterial protein synthesis.

a. The aminoglycosides


Aminoglycosides (streptomycin, neomycin, netilmicin, tobramycin, gentamicin, amikacin, etc.) **bind irreversibly to the 16S rRNA in the 30S subunit** of bacterial ribosomes. Although the exact mechanism of action is still uncertain, there is evidence that some prevent the transfer of the peptidyl tRNA from the A-site to the P-site, thus preventing the elongation of the polypeptide chain. Some aminoglycosides also appear to interfere with the proofreading process that helps assure the accuracy of translation (**see Fig.13**). Possibly the antibiotics reduce the rejection rate for tRNAs that are near matches for the codon. This leads to misreading of the codons or premature termination of protein synthesis (**see Fig.14**). Aminoglycosides may also interfere directly or indirectly with the function of the bacterial cytoplasmic membrane. Because of their toxicity, aminoglycosides are generally used only when other first line antibiotics are not effective.

Fig. 13: Aminoglycosides Interfering with the Translocation of tRNA from the A-site to the P-site



The aminoglycosides (streptomycin, neomycin, netilmicin, tobramycin, gentamicin, amikacin, etc.) bind irreversibly to the 16S rRNA in the 30S subunit of bacterial ribosomes. It has been proposed that some aminoglycosides prevent the transfer of the peptidyl tRNA from the A-site to the P-site, thus preventing the elongation of the polypeptide chain.

Fig. 14: Aminoglycosides Interfering with Translation by causing a Misreading of the Codons along the mRNA



The aminoglycosides (streptomycin, neomycin, netilmicin, tobramycin, gentamicin, amikacin, etc.) bind irreversibly to the 16S rRNA in the 30S subunit of bacterial ribosomes. It has been proposed that some aminoglycosides interfere with the proofreading process that helps assure the accuracy of translation. Possibly the antibiotics reduce the rejection rate for tRNAs that are near matches for the codon. This leads to misreading of the codons or premature termination of protein synthesis.

Flash animation illustrating aminoglycosides preventing the translocation of tRNA from the A-site to the P-site of bacterial ribosomes.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating aminoglycosides preventing the translocation of tRNA from the A-site to the P-site of bacterial ribosomes.

The aminoglycosides (streptomycin, neomycin, netilmicin, tobramycin, gentamicin, amikacin, etc.) bind irreversibly to the 16S rRNA in the 30S subunit of bacterial ribosomes. It has been proposed that some aminoglycosides prevent the transfer of the peptidyl tRNA from the A-site to the P-site, thus preventing the elongation of the polypeptide chain.

Flash animation illustrating aminoglycosides causing a misreading of codons.

Copyright © Gary E. Kaiser


html5 version of animation for iPad illustrating aminoglycosides causing a misreading of codons.

The aminoglycosides (streptomycin, neomycin, netilmicin, tobramycin, gentamicin, amikacin, etc.) bind irreversibly to the 16S rRNA in the 30S subunit of bacterial ribosomes. It has been proposed that some aminoglycosides

interfere with the proofreading process that helps assure the accuracy of translation. Possibly the antibiotics reduce the rejection rate for tRNAs that are near matches for the codon. This leads to misreading of the codons or premature termination of protein synthesis.

b. The tetracyclines

Tetracyclines (tetracycline, doxycycline, demeclocycline, minocycline, etc.) **bind reversibly to the 16S rRNA in the 30S ribosomal subunit**, distorting it in such a way that the **anticodons of charged tRNAs cannot align properly with the codons of the mRNA** (see Fig. 15).



The tetracyclines (tetracycline, doxycycline, demeclocycline, minocycline, etc.) block bacterial translation by binding reversibly to the 16S rRNA in the 30S subunit and distorting it in such a way that the anticodons of the charged tRNAs cannot align properly with the codons of the mRNA.

Flash animation illustrating how tetracyclines bind to the 30S ribosomal subunit and block translation.


Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating how tetracyclines bind to the 30S ribosomal subunit and block translation.

The tetracyclines (tetracycline, doxycycline, demeclocycline, minocycline, etc.) block bacterial translation by binding reversibly to the 16S rRNA in the 30S subunit and distorting it in such a way that the anticodons of the charged tRNAs cannot align properly with the codons of the mRNA.


c. The macrolides

Macrolides (erythromycin, azithromycin, clarithromycin, dirithromycin, troleandomycin, etc.) **bind reversibly to the 23S rRNA in the 50S subunit** of bacterial ribosomes. They appear to **inhibit elongation of the protein by preventing the enzyme peptidyltransferase** from forming peptide bonds between the amino acids (see Fig. 15). They may also **prevent the transfer of the peptidyl tRNA from the A-site to the P-site** (see Fig. 16) as the beginning peptide chain on the peptidyl tRNA adheres to the ribosome, creates friction, and blocks the exit tunnel of the 50S ribosomal subunit.



The macrolides (erythromycin, azithromycin, clarithromycin, dirithromycin, troleandomycin, etc.) bind reversibly to the 23S rRNA in the 50S subunit. There is evidence that they may inhibit elongation of the protein by the peptidyltransferase, the enzyme that forms peptide bonds between the amino acids.

Fig. 16: Mode of Action of Macrolides in Blocking Translation by Preventing the Transfer of the Peptidyl tRNA from the A-site to the P-site



Copyright © Gary E. Kaiser

The macrolides (erythromycin, azithromycin, clarithromycin, dirithromycin, troleandomycin, etc.) bind reversibly to the 23S rRNA in the 50S subunit. There is evidence that they may inhibit elongation of the protein by preventing the enzyme peptidyltransferase from forming peptide bonds between the amino acids. They may also prevent the transfer of the peptidyl tRNA from the A-site to the P-site as shown here.

Flash animation illustrating how macrolides bind to the 50S ribosomal subunit and block translation by blocking peptidyltransferase.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating how macrolides bind to the 50S ribosomal subunit and block translation by blocking peptidyltransferase.

The macrolides (erythromycin, azithromycin, clarithromycin, dirithromycin, troleandomycin, etc.) bind reversibly to the 23S rRNA in the 50S subunit. There is evidence that they may inhibit elongation of the protein by the peptidyltransferase, the enzyme that forms peptide bonds between the amino acids.

Flash animation illustrating how macrolides bind to the 50S ribosomal subunit and block translation by preventing the transfer of peptidyl tRNA from the A-site to the P-site.

Copyright © Gary E. Kaiser


html5 version of animation for iPad illustrating how macrolides bind to the 50S ribosomal subunit and block translation by preventing the transfer of peptidyl tRNA from the A-site to the P-site.

The macrolides (erythromycin, azithromycin, clarithromycin, dirithromycin, troleandomycin, etc.) bind reversibly to the 23S rRNA in the 50S subunit. There is evidence that they may inhibit elongation of the protein by preventing the enzyme peptidyltransferase from forming peptide bonds between the amino acids. They may also prevent the transfer of the peptidyl tRNA from the A-site to the P-site as shown here.

d. The oxazolidinones

Oxazolidinones (linezolid, sivextro), following the first cycle of protein synthesis, interfere with translation sometime before the initiation phases. They appear to bind to the 50S ribosomal subunit and interfere with its binding to the initiation complex (see Fig. 17).

Fig. 17: Mode of Action of Oxazolidinones Blocking the Attachment of the 50S Ribosomal Subunit to the Initiation Complex



The oxazolidinones (linezolid) bind to the 23S rRNA in the 50S ribosomal subunit and interfere with the formation of the initiation complex.

Flash animation illustrating how oxazolidinones block the binding of the 50S ribosomal subunit to the initiation complex.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating how oxazolidinones block the binding of the 50S ribosomal subunit to the initiation complex.

The oxazolidinones (linezolid) bind to the 23S rRNA in the 50S ribosomal subunit and interfere with the formation of the initiation complex.

e. The streptogramins

Streptogramins (synercid, a combination of quinupristin and dalfopristin) **bind to two different locations on the 23S rRNA in the 50S ribosomal subunit** and **work synergistically** to block translation. There are reports that the streptogramins may inhibit the attachment of the charged tRNA to the A-site or may block the peptide exit tunnel of the 50S ribosomal subunit.

Common Antibacterial Antibiotics

Concept map for Chemical Agents that Inhibit RNA Polymerase, Alter Prokaryotic Ribosomes, or Denature Enzymes

For a more detailed description of any specific antimicrobial agent, see the website of RxList - The Internet Drug Index.

TPS Questions

Self Check



6. Modes of Action for Disinfectants, Antiseptics, and Sanitizers.

Disinfectants, antiseptics, and sanitizers

Disinfection is the elimination of microorganisms, but not necessarily endospores, from inanimate objects or surfaces, whereas decontamination is the treatment of an object or inanimate surface to make it safe to handle. **Sterilization** on the other hand, is the process of destroying all living organisms and viruses. A sterile object is one free of all life forms, including bacterial endospores, as well as viruses. **Decontamination** refers to the treatment of an object or inanimate surface to make it safe to handle.

The term disinfectant is used for an agent used to disinfect inanimate objects or surfaces but is generally too toxic to use on human tissues. Antiseptic refers to an agent that kills or inhibits growth of microbes but is safe to use on human tissue. **Sanitizer** describes an agent that reduces microbial numbers to a safe level. Because **disinfectants, antiseptics, and sanitizers** often work slowly on some viruses - such as the hepatitis viruses, bacteria with an acid-fast cell wall such as *Mycobacterium tuberculosis*, and especially bacterial endospores, produced by the genus *Bacillus* and the genus *Clostridium*, they **are usually unreliable for sterilization** - the destruction of all life forms and viruses.

There are a number of **factors which influence the antimicrobial action of disinfectants, antiseptics, and sanitizers**, including:

1. The concentration of the chemical agent.
2. The temperature at which the agent is being used. Generally, the lower the temperature, the longer it takes to disinfect or decontaminate.
3. The kinds of microorganisms present. Endospore producers such as *Bacillus* species, *Clostridium* species, and acid-fast bacteria like *Mycobacterium tuberculosis* are harder to eliminate.
4. The number of microorganisms present. The more microorganisms present, the harder it is to disinfect or decontaminate.
5. The nature of the material bearing the microorganisms. Organic material such as dirt and excreta interferes with some agents.

The best results are generally obtained when the initial **microbial numbers are low** and when the **surface to be disinfected is clean** and free of possible interfering substances.

Concept map for Lab 19 - Using disinfectants, antiseptics, and sanitizers to control microorganisms

There are 2 common antimicrobial **modes of action** for disinfectants, antiseptics, and sanitizers:

1. They may **damage the lipids and/or proteins of the semipermeable cytoplasmic membrane** of microorganisms resulting in **leakage of cellular materials** needed to sustain life.
2. They may **denature microbial enzymes and other proteins**, usually by disrupting the hydrogen and disulfide bonds that give the protein its three-dimensional functional shape. This **blocks metabolism**.

A large number of such chemical agents are in common use. Some of the more common groups are listed below:

1. Phenol and phenol derivatives

Phenol (5-10%) was the first disinfectant commonly used. However, because of its toxicity and odor, phenol derivatives (phenolics) are now generally used. The most common phenolic is orthophenylphenol, the agent found in O-syl®, Staphene®, and Amphy®. Bisphenols contain two phenolic groups and typically have chlorine as a part of their structure. They include hexachlorophene and triclosan. Hexachlorophene in a 3% solution is combined with detergent and is found in PhisoHex®. Triclosan is an antiseptic very common in antimicrobial soaps and other products. Biguanides include chlorhexadine and alexidine. A 4% solution of chlorhexidine in isopropyl alcohol and combined with detergent (Hibiclens® and Hibitane®) is a common hand washing agent and surgical hand scrub. These agents kill most bacteria, most fungi, and some viruses, but are usually ineffective against endospores. Chloroxyleneol (4-chloro-3,5-dimethylphenol) is a broad spectrum antimicrobial chemical compound used to control bacteria, algae, fungi and virus and is often used in antimicrobial soaps and antiseptics. Phenol and phenolics alter membrane permeability and denature proteins. Bisphenols, biguanides, and chloroxyleneol alter membrane permeability.

2. Soaps and detergents

Soaps are only mildly microbicidal. Their use aids in the mechanical removal of microorganisms by breaking up the oily film on the skin (emulsification) and reducing the surface tension of water so it spreads and penetrates more readily. Some cosmetic soaps contain added antiseptics to increase antimicrobial activity. Detergents may be anionic or cationic. Anionic (negatively charged) detergents, such as laundry powders, mechanically remove microorganisms and other materials but are not very microbicidal. Cationic (positively charged) detergents alter membrane permeability and denature proteins. They are effective against many vegetative bacteria, some fungi, and some viruses. However, bacterial endospores and certain bacteria such as *Mycobacterium tuberculosis* and *Pseudomonas* species are usually resistant. Soaps and organic materials like excreta also inactivate them. Cationic detergents include the quaternary ammonium compounds such as benzalkonium chloride, zephiran®, diaprene, roccal, ceepryn, and phemerol. Household Lysol® contains alkyl dimethyl benzyl ammonium chloride and alcohols.

3. Alcohols

70% solutions of ethyl or isopropyl alcohol are effective in killing vegetative bacteria, enveloped viruses, and fungi. However, they are usually ineffective against endospores and non-enveloped viruses. Once they evaporate, their cidal activity will cease. Alcohols denature membranes and proteins and are often combined with other disinfectants, such as iodine, mercurials, and cationic detergents for increased effectiveness.

4. Acids and alkalies

Acids and alkalies alter membrane permeability and denature proteins and other molecules. Salts of organic acids, such as calcium propionate, potassium sorbate, and methylparaben, are commonly used as food preservatives. Undecylenic acid (Desenex®) is used for dermatophyte infections of the skin. An example of an alkali is lye (sodium hydroxide).

5. Heavy metals

Heavy metals, such as mercury, silver, and copper, denature proteins. Mercury compounds (mercurochrome, metaphen, merthiolate) are only bacteriostatic and are not effective against endospores. Silver nitrate (1%) is sometimes put in the eyes of newborns to prevent gonococcal ophthalmia. Copper sulfate is used to combat fungal diseases of plants and is also a common algicide. Selenium sulfide kills fungi and their spores.

6. Chlorine

Chlorine gas reacts with water to form hypochlorite ions, which in turn denature microbial enzymes. Chlorine is used in the chlorination of drinking water,

swimming pools, and sewage. Sodium hypochlorite is the active agent in household bleach. Calcium hypochlorite, sodium hypochlorite, and chloramines (chlorine plus ammonia) are used to sanitize glassware, eating utensils, dairy and food processing equipment, hemodialysis systems, and treating water supplies.

7. Iodine

Iodine also denatures microbial proteins. Iodine tincture contains a 2% solution of iodine and sodium iodide in 70% alcohol. Aqueous iodine solutions containing 2% iodine and 2.4% sodium iodide are commonly used as a topical antiseptic. Iodophores are a combination of iodine and an inert polymer such as polyvinylpyrrolidone that reduces surface tension and slowly releases the iodine. Iodophores are less irritating than iodine and do not stain. They are generally effective against vegetative bacteria, *Mycobacterium tuberculosis*, fungi, some viruses, and some endospores. Examples include Wescodyne®, Ioprep®, Ioclode®, Betadine®, and Isodine®.

8. Aldehydes

Aldehydes, such as formaldehyde and glutaraldehyde, denature microbial proteins. Formalin (37% aqueous solution of formaldehyde gas) is extremely active and kills most forms of microbial life. It is used in embalming, preserving biological specimens, and in preparing vaccines. Alkaline glutaraldehyde (Cidex®), acid glutaraldehyde (Sonacide®), and glutaraldehyde phenate solutions (Sporocidin®) kill vegetative bacteria in 10-30 minutes and endospores in about 4 hours. A 10 hour exposure to a 2% glutaraldehyde solution can be used for cold sterilization of materials. *Ortho*-phthalaldehyde (OPA) is dialdehyde used as a high-level disinfectant for medical instruments.

9. Peroxygens

Peroxygens are oxidizing agents that include hydrogen peroxide and peracetic acid. Hydrogen peroxide is broken down into water and oxygen by the enzyme catalase in human cells and is not that good of an antiseptic for open wounds but is useful for disinfecting inanimate objects. The high concentrations of hydrogen peroxide overwhelm the catalase found in microbes. Peracetic acid is a disinfectant that kills microorganisms by oxidation and subsequent disruption of their cytoplasmic membrane. It is widely used in healthcare, food processing, and water treatment.

10. Ethylene oxide gas

Ethylene oxide is one of the very few chemicals that can be relied upon for sterilization (after 4-12 hours exposure). Since it is explosive, it is usually mixed with inert gases such as freon or carbon dioxide. Gaseous chemosterilizers, using ethylene oxide, are commonly used to sterilize heat-sensitive items such as plastic syringes, Petri plates, textiles, sutures, artificial heart valves, heart-lung machines, and mattresses. Ethylene oxide has very high penetrating power and denatures microbial proteins. Vapors are toxic to the skin, eyes, and mucous membranes and are also carcinogenic. Another gas that is used as a sterilant is chlorine dioxide which denatures proteins in vegetative bacteria, bacterial endospores, viruses, and fungi.

Self Quiz for Ways in which Our Chemical Control Agents may Affect Bacteria

Quiz Group



[Back to Unit 2 Table of Contents](#)

[Back to Softchalk Lessons Table of Contents](#)

Common Course Objectives

1. Define terms used in describing the methods of microbial control.
2. Recall the mechanism of action for each class of chemotherapeutic chemical agent and give specific examples for each class.
3. Identify appropriate methods of microbial control under a given specific circumstance.
4. Recall the advantages and disadvantages of the different types of chemical control.
5. Identify clinically appropriate methods of growth inhibition when given a specific microbe.
6. Recall different mechanisms as a result of genetic changes in a bacterium that may enable that bacterium to resist an antibiotic.

Detailed Learning Objectives

1. Name 2 bacteria that have low-permeability membrane barriers and are thereby intrinsically resistant to many antibiotics.
- 2**. Briefly describe 4 different mechanisms occurring as a result of genetic changes in a bacterium that may enable that bacterium to resist an antibiotic.
- 3*. Describe R (Resistance) plasmids and state their significance to medical microbiology.
4. State what the following stand for: MRSA, VRE, CREs, ESBLs, and XDR TB.
5. Define dormant persisters and antibiotic tolerance.

(*) = Common theme throughout the course

(**) = More depth and common theme

TPS Questions

Ways in which Bacteria may Resist Chemical Control Agents

Some opportunistic pathogens, such as *Pseudomonas aeruginosa*, *Mycobacterium tuberculosis*, and *Enterococcus* species, have **low-permeability membrane barriers** and are thereby **intrinsically resistant to many antibiotics**. Most bacteria, however, become **resistant to antibiotics** as a result of mutation or genetic recombination. Mutation in bacterial DNA can alter the order of nucleotide bases in a gene and alter that gene product. Horizontal gene transfer can alter or add bacterial genes, again altering the bacterium's gene products.

For more information: See function of DNA.

Most bacteria, become **resistant to antibiotics** by way of one or more of the following mechanisms that are coded for by genes in the bacterial chromosome or in plasmids:

1. Producing an enzyme capable of inactivating the antibiotic;
2. Altering the target site receptor for the antibiotic to reduce or block its binding;
3. Preventing the entry of the antibiotic into the bacterium and/or using an efflux pump to transport the antibiotic out of the bacterium; and/or
4. Modulating gene expression to produce more of the bacterial enzyme that is being tied up or altered by the antibiotic.

Nice 2013 summary of antibiotic resistant cases and associated deaths; from the CDC

Article: Improving antibiotic use among hospitalized patients; a 2014 report from the CDC

Article: Estimates of Healthcare-Associated Infections (HCIs) 2011; from the CDC

Article: Getting Smart About Antibiotics; a 2015 report from the CDC.


Preventing Antibiotic-Resistant Infections in Hospitals - United States, 2014; a 2016 report from CDC.

WHO publishes list of bacteria for which new antibiotics are urgently needed. January, 2017

In the following pages we will look at each of these mechanisms of resistance.


1. Producing enzymes that inactivate the antibiotic

Bacteria may acquire new genes that code for an enzyme that inactivates a particular antibiotic or group of antibiotics (see Fig. 1).



For example:

a. Bacteria typically become resistant to penicillins, monobactams, carbapenems, and cephalosporins are known chemically as beta-lactam antibiotics (see Fig. 2) and many bacteria become resistant to these antibiotics by producing various beta-lactamases that are able to inactivate some forms of these drugs. **Beta-lactamases break the beta-lactam ring of the antibiotic, thus inactivating the drug.** (Penicillinase is a beta-lactamase that inactivates certain penicillins.) To overcome this mechanism of resistance, sometimes beta-lactam antibiotics such as amoxicillin, ticarcillin, imipenem, or ampicillin are combined with **beta-lactamase inhibitors** such as clavulanate, tazobactam, or sulbactam (see Common Antibiotics) - chemicals that resemble beta-lactam antibiotic (see Fig. 2). These agents bind to the bacterial beta-lactamases and **neutralize them**.



b. Bacteria may **become resistant to aminoglycosides** (streptomycin, neomycin, netilmicin, tobramycin, gentamicin, amikacin, etc.) and streptogramins **by enzymatically adding new chemical groups to these antibiotics**, thus inactivating the drug.

Flash animation showing a bacterium producing an enzyme capable of inactivating the antibiotic

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing a bacterium producing an enzyme capable of inactivating the antibiotic

A gene in the chromosome or in a plasmid may code for production of an enzyme that is able to inactivate a particular antibiotic.


Concept map for Ways in Which Bacteria Resist Antibiotics and Chemical Agents

2. Altering the target site receptor for the antibiotic in the bacterium to reduce or block its binding.

Antibiotics work by binding to some bacterial target site, such as a 50S ribosomal subunit, a 30S ribosomal subunit, or a particular bacterial enzyme such as a transpeptidase or a DNA topoisomerase. Bacteria may acquire new genes that alter the molecular shape of the portion of the ribosomal subunit or the enzyme to which the drug normally binds. For example:

- a. Bacteria may become resistant to macrolides (erythromycin, azithromycin, clarithromycin, dirithromycin, troleandomycin, etc.) by producing a slightly altered 50S ribosomal subunit that still functions but to which the antibiotic can no longer bind (see Fig. 3).

Fig. 3: Altering the Target Site for the Antibiotic to Reduce or Block its Binding: Producing an Altered Ribosomal Subunit




Copyright © Gary E. Kaiser

A bacterium altering the target site of the antibiotic, in this case a 50S ribosomal subunit. The drug is no longer able to bind to the ribosome and block protein synthesis.

- b. Bacteria may become resistant to beta-lactam antibiotics (penicillins, monobactams, carbapenems, and cephalosporins) by producing altered transpeptidases (penicillin-binding proteins) with greatly reduced affinity for the binding of beta-lactam antibiotics.
- c. Bacteria may become resistant to vancomycin by producing altered cross-linking peptides in the peptidoglycan to which the antibiotic no longer binds.
- d. Bacteria may become resistant to fluoroquinolones (norfloxacin, lomefloxacin, fleroxacin, ciprofloxacin, enoxacin, trovafloxacin, etc.) by producing altered DNA gyrase or other topoisomerases to which the drug no longer binds (see Fig. 4).

Fig. 4: Altering the Target Site for the Antibiotic to Reduce or Block its Binding: Producing an Altered Enzyme



Copyright © Gary E. Kaiser

A bacterium altering the target site of the antibiotic, in this case an enzyme. The drug is no longer able to bind to the enzyme and block the enzyme from reacting with its substrate.

Flash animation showing a bacterium producing an altered ribosomal subunit to which the antibiotic no longer binds.

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing a bacterium producing an altered ribosomal subunit to which the antibiotic no longer binds.

Some antibiotics work by binding to a bacterial ribosomal subunit, altering the ribosome, and blocking bacterial protein synthesis. This bacterium becomes resistant to the antibiotic by altering the antibiotic's target site, in this case a 50S ribosomal subunit. The drug is no longer able to bind to the ribosome and the bacterium can still carry out normal protein synthesis.

Flash animation showing a bacterium producing an altered enzyme to which the antibiotic no longer binds.

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing a bacterium producing an altered enzyme to which the antibiotic no longer binds.

A bacterium can become resistant to an antibiotic by altering the antibiotic's target site, in this case the antibiotic-binding site of the bacterial enzyme. Since the drug is no longer able to bind to the enzyme, the active site of the enzyme is not altered and the enzyme is able to bind to its normal substrate.

For more information: [Review of bacterial ribosomes](#)

For more information: [Review of peptidoglycan](#)


For more information: [Review of the bacterial chromosome and nucleoid](#)

Concept map for [Ways in Which Bacteria Resist Antibiotics and Chemical Agents](#)


3. Altering the membranes and transport systems to prevent the entry of the antibiotic into the bacterium and/or using an efflux pump to transport the antibiotic out of the bacterium.

Antibiotics that target ribosomes or enzymes within the bacterium must first pass through the porins in the outer membrane of Gram-negative and acid-fast bacterial cell walls, and then the cytoplasmic membrane in the case of all bacteria. Subsequently, the antibiotic has to accumulate to a high enough concentration within the bacterium to inhibit or kill the organism.


a. A Gram-negative or an acid-fast bacterium may block the entry of an antimicrobial drug by acquiring genes that alter the porins in the cell wall's outer membrane (see Fig. 5).




b. A bacterium may block the entry of an antimicrobial drug by acquiring genes that alter the transport proteins used to transport the drug through the bacterium's cytoplasmic membrane (see Fig. 6). This is generally not a common mechanism of antibiotic resistance.



c. A bacterium may acquire genes coding for an energy-driven efflux pump in its the cytoplasmic membrane that is able to to pump the antibiotic out of the bacterium and preventing it from accumulating to a high enough concentration to inhibit or kill the organism (see Fig. 7). This is the most common method bacteria use to prevent toxic levels of antimicrobial drugs from accumulating within the cytoplasm.





Copyright © Gary E. Kaiser

A bacterium producing transporter molecules that pump the antibiotic out of the bacterium.

Flash animation showing a bacterium producing altered porins to block transport of the drug across the outer membrane.

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing a bacterium producing altered porins to block transport of the drug across the outer membrane.

Some Gram-negative bacteria become resistant to an antibiotic by producing altered porins in their outer membrane. The antibiotic is no longer able to pass through the outer membrane.

Flash animation showing a bacterium producing an altered transport protein to block transport of the drug across the cytoplasmic membrane.

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing a bacterium producing an altered transport protein to block transport of the drug across the cytoplasmic membrane.

Some bacteria become resistant to an antibiotic by producing an altered transport (carrier) protein in the cytoplasmic membrane. This new carrier protein is no longer able to transport the antibiotic across the cytoplasmic membrane into the cytoplasm.

Flash animation showing a bacterium producing a new transport protein able to pump the drug out of the bacterium.

Copyright © Gary E. Kaiser

html5 version of animation for iPad showing a bacterium producing a new transport protein able to pump the drug out of the bacterium.

Some bacteria become resistant to an antibiotic by producing new efflux pump that pumps the antibiotic back out of the bacterium.

For more information: Review of the bacterial cytoplasmic membrane


Concept map for Ways in Which Bacteria Resist Antibiotics and Chemical Agents

4. Modulating gene expression to produce more of the bacterial enzyme that is being tied up or altered by the antibiotic.

Remember that enzymes function as catalysts and are present in cells in small amounts because they are not altered as they carry out their specific biochemical reactions. As mentioned in the previous section, numerous antimicrobial drugs work by inactivating bacterial enzymes and blocking metabolic reactions. Making a particular enzyme and the amount of enzyme that is made is under genetic control.


Genetic control of enzyme activity refers to controlling transcription of the mRNA needed for an enzyme's synthesis. In prokaryotic cells, this involves the induction or repression of enzyme synthesis by regulatory proteins that can bind to DNA and either block or enhance the function of RNA polymerase, the enzyme required for transcription.

Bacteria also use translational control of enzyme synthesis. In this case, the bacteria produce noncoding regulatory RNAs (ncRNAs) or antisense RNAs such as micro RNAs (miRNAs) that are complementary to the early portion of a mRNA coding for the enzyme. When the noncoding regulatory RNA binds to the mRNA by complementary base pairing, ribosomes cannot attach to the mRNA, the mRNA cannot be translated into protein, and the enzyme is not made (**See Fig. 8**).



For more information: Review of enzyme regulation

Mutations or horizontal gene transfer may result in a modulation of gene expression or translational events that favor increased production of the enzyme being tied up or altered by the antimicrobial agent (see Fig. 9). Since enzymes are normally produced in limited amounts, production of excessive amounts of enzyme may allow for the metabolic activity being blocked by the agent to still occur.



Flash animation illustrating competitive antagonism.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating competitive antagonism.

Competitive antagonism is a process whereby a drug chemically resembles a substrate in a metabolic pathway. Because of their similarity, either the drug or the substrate can bind to the substrate's enzyme. When the bacterial enzyme binds to its normal substrate, an enzyme-substrate complex forms and the end products required by that bacterium are made. When the enzyme is bound to the drug, it is unable to bind to its natural substrate and that blocks the production of the end products of that metabolic pathway. If enough drug is present in the bacterium, all of the bacterial enzyme - which is normally present in the cell only in limited amounts - is tied up with the drug and the end products needed for the bacterium's metabolism are not

produced.

Flash animation showing a bacterium producing more of a limited enzyme.

Copyright © Gary E. Kaiser

Flash animation showing a bacterium producing more of a limited enzyme.

A bacterium becoming resistant to an antimicrobial agent by producing greater amounts of the limited enzyme being tied up or inactivated by the drug. Although some enzyme is tied up by the drug, there is still enzyme available to react with its substrate and produce end products.

GIF animation illustrating antisense RNA

TPS Questions

Class activity

Watch University of Texas at San Antonio microbiologist Karl Klose discusses the problem of antibiotic resistance in a 2013 TED talk.

Use your notes to name and describe the bacterial mechanisms of antibiotic resistance referred to in this talk as "upchuck," "stealth mode," and "ballistic missile."

Concept map for Ways in Which Bacteria Resist Antibiotics and Chemical Agents

5. Many pathogenic bacteria, as well as normal flora, form complex bacterial communities as biofilms.

Bacteria in biofilms are often able to communicate with one another by a process called quorum sensing and are able to interact with and adapt to their environment as a population of bacteria rather than as individual bacteria. By living as a community of bacteria as a biofilm, these bacteria are:

- better able to resist attack by antibiotics**, and
- better able to resist the host immune system**.

Why bacterium within a biofilm are more antibiotic resistant isn't completely understood but various mechanisms have been proposed. The extracellular polysaccharide may make it more difficult for the antibiotic to reach all of the bacteria. Bacteria within a biofilm are generally in a metabolically more inert state and this could slow down antibacterial action of the drug. Many antibiotics are static, not cidal in action; the body depends on phagocytes to remove the inhibited bacteria. The biofilm structure makes engulfment by phagocytes pretty much impossible.

6. Dormant persisters

Another mechanism that protects some bacteria from antibiotics is antibiotic tolerance. In the case of **antibiotic tolerance, the tolerant bacterium is not killed but simply stops growing when the antibiotic is present**. It then is able to recover once the antibiotic is no longer in the host. For example, *Streptococcus pneumoniae* tolerant to vancomycin appear to repress their autolysins in the presence of the drug and don't undergo osmotic lysis. Antibiotic tolerance is especially significant in terms of bacteria that form biofilms associated with catheters, heart valves, orthopedic devices, and people with cystic fibrosis. These biofilms often contain a small percentage of dormant persisters that, because they are not dividing, tolerate the antibiotics.

Its been found that bacteria simultaneously produce toxins that inhibit their own growth and antitoxins that bind to the toxin and cause its neutralization. Small

numbers of bacteria in the population, however, become persisters because they produce lower levels of antitoxin or the antitoxin is degraded by stress. As a result, the free toxin arrests bacterial growth enabling a persistent state that is able to survive stressors such as antibiotics and starvation.

The above changes in the bacterium that enable it to resist the antibiotic occur naturally as a result of mutation or as a result of horizontal gene transfer.

Mutation rate in bacteria

For example, when under stress from antibiotics, some bacteria switch on genes whose protein products can **increase the mutation rate within the bacterium 10,000 times as fast as the mutation rate that occurs during normal binary fission**. This causes a sort of hyperevolution where mutation acts as a self defense mechanism for the bacterial population by increasing the chance of forming an antibiotic-resistant mutant that is able to survive at the expense of the majority of the population. (Remember that most mutations are harmful to a cell.)

For more information: Review of mutation

Evolution of *Escherichia coli* Antibiotic Resistance via Mutation over Space and Time

Courtesy of Havard Medical School

In addition, horizontal gene transfer as a result of transformation, transduction, and conjugation can transfer antibiotic resistance from one bacterium to another. Horizontal gene transfer enables bacteria to respond and adapt to their environment much more rapidly than mutation by acquiring large DNA sequences from another bacterium in a single transfer.

For more information: Review of horizontal gene transfer

Concept map for Ways in Which Bacteria Resist Antibiotics and Chemical Agents

Examples of bacterial antibiotic resistance

Exposure to the antibiotic typically **selects for strains of the organism that have become resistant** through these natural processes. Misuse of antibiotics, such as prescribing them for non-bacterial infections (colds, influenza, most upper respiratory infections, etc.) or prescribing the "newest" antibiotic on the market when older brands may still be as effective simply increases the rate at which this natural selection for resistance occurs. According to the Centers for Disease Control and Prevention, as many as one-third (50 million out of 150 million) of antibiotic prescriptions given on an outpatient basis are unneeded. Patient noncompliance with antimicrobial therapy, namely, not taking the prescribed amount of the antibiotic at the proper intervals for the appropriate length of time, also plays a role in selecting for resistant strains of bacteria.

The spread of antibiotic resistance in pathogenic bacteria is due to both direct selection and indirect selection.

1. **Direct selection** refers to the **selection of antibiotic resistant pathogens at the site of infection**.
2. **Indirect selection** is the **selection of antibiotic-resistant normal flora** within an individual anytime an antibiotic is given. At a later date, **these resistant normal flora may transfer resistance genes to pathogens** that enter the body. In addition, **these resistant normal flora may be transmitted from person to person through such means as the fecal-oral route or through respiratory secretions**.

As an example, many Gram-negative bacteria possess **R (Resistance) plasmids** that have genes coding for **multiple antibiotic resistance** through the mechanisms learned above, as well as transfer genes coding for a **conjugation (sex) pilus**. It is possible for R-plasmids to **accumulate transposons** to increase bacterial resistance. Such an organism can conjugate with other bacteria and transfer to them an R plasmid. *E. coli*, *Proteus*, *Serratia*, *Enterobacter*, *Salmonella*, *Shigella*, and *Pseudomonas* are bacteria that frequently have R-factor plasmids.

Flash animation illustrating R-plasmid conjugation.

Copyright © Gary E. Kaiser

html5 version of animation for iPad illustrating R-plasmid conjugation.

R plasmids are conjugative plasmids coding for mating pair formation and also multiple antibiotic resistance. A

conjugative plasmid is self-transmissible, in that it possesses all the necessary genes for that plasmid to transmit itself to another bacterium by conjugation. Conjugation genes known as *tra* genes enable the bacterium to form a mating pair with another organism, while *oriT* (origin of transfer) genes determine where on the plasmid DNA transfer is initiated. The plasmid also possess genes coding for resistance to a number of different antibiotics.

In addition to plasmids, **conjugative transposons also frequently transmit antibiotic resistance from one bacterium to another**. Conjugative transposons, like conjugative plasmids, carry the genes that enable mating pairs to form for conjugation. Therefore, conjugative transposons also enable mobilizable plasmids and nonconjugative transposons to be transferred to a recipient bacterium during conjugation.

For more information: Review of horizontal gene transfer

Examples of resistant strains of bacteria of ever increasing medical importance include:

1. Antibiotic-Resistant *Neisseria gonorrhoeae*

Out of an estimated 820,000 *Neisseria gonorrhoeae* infections per year, 246,000 are antibiotic-resistant.

2. Carbapenem-Resistant *Enterobacteriaceae* (CRE)

More recently, carbapenemase-producing *Klebsiella pneumoniae* (KPC) strains are frequently being identified among nosocomial pathogens globally. Carbapenemase is a broad-spectrum beta-lactamase enzyme first found in *K. pneumoniae* isolates that results in **resistance to all penicillins, cephalosporins, carbapenems** (i.e., imipenem, ertapenem, meropenem), **and monobactams** (i.e., aztreonam). These broad-spectrum beta-lactamases are also known as **extended spectrum beta-lactamases or ESBLs**. These ESBLs are now being seen in a variety *Enterobacteriaceae* including *Enterobacter* spp., *E. coli*, *Serratia* spp., and *Salmonella enterica*. **These ESBL-producing *Enterobacteriaceae* are known as carbapenem-resistant *Enterobacteriaceae*, or CRE**. Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection.

3. Methicillin-resistant *Staphylococcus aureus* (MRSA)

Staphylococcus aureus resistance to methicillin confers resistance to all penicillins and cephalosporins.

4. Vancomycin-resistant *Enterococcus* (VRE)

Vancomycin-resistant *Enterococcus* (VRE) are intrinsically resistant to most antibiotics and have acquired resistance to the first line drug of choice, vancomycin.

5. XDR TB

Extensively drug-resistant tuberculosis (XDR TB), a relatively rare type of multidrug-resistant *Mycobacterium tuberculosis* that is resistant to almost all drugs used to treat TB, including the two best first-line drugs: isoniazid and rifampin. XDR TB is also resistant to the best second-line medications: fluoroquinolones and at least one of three injectable drugs i.e., amikacin, kanamycin, or capreomycin.

6. *Clostridium difficile* infections

A 2015 CDC study found that "*Clostridium difficile* caused **almost half a million infections among patients in the United States in a single year**. An **estimated 15,000 deaths** are directly attributable to *C. difficile* infections, making it a substantial cause of infectious disease death in the United States" with an excess medical cost of \$1,000,000,000 per year.

CDC's top 18 drug-resistant threats to the US

Bacteria such as *E. coli*, *Proteus*, *Enterobacter*, *Serratia*, *Pseudomonas*, *Staphylococcus aureus*, and *Enterococcus* mentioned above, are the leading cause of **health care-associated infections**. According to the Centers for Disease Control and Prevention (CDC) Healthcare-associated infection's website, "**In American hospitals alone, healthcare-associated infections account for an estimated 1.7 million infections and 99,000 associated deaths each year**" in the U.S. The CDC also estimates that "**more than two million people in the United States get infections that are resistant to antibiotics and at least 23,000 people die as a result.**"

Finally, Bacterial **endospores**, such as those produced by *Bacillus* and *Clostridium*, are also resistant to antibiotics, most disinfectants, and physical agents such as boiling and drying. Although harmless themselves, they are involved in the transmission of some diseases to humans. Examples include anthrax (*Bacillus anthracis*), tetanus (*Clostridium tetani*), botulism (*Clostridium botulinum*), gas gangrene (*Clostridium perfringens*), and pseudomembranous colitis (*Clostridium difficile*).

Self Quiz for Ways Bacteria Resist Chemical Control Agents

Quiz Group



[Back to Unit 2 Table of Contents](#)

[Back to Softchalk Lessons Table of Contents](#)